Category: 3. Business

MTN is proud to once again be part of MWC Kigali, Africa’s leading technology event, taking place from 21 – 23 October 2025 at the Kigali Convention Centre, Rwanda. Hosted by the GSMA, the gathering brings together government, industry and technology leaders to explore how digital innovation can unlock inclusive growth across the continent.

For MTN, MWC Kigali is an opportunity to showcase progress across our networks, fintech, digital services and skills initiatives, while engaging with policymakers and partners to secure an inclusive and sustainable digital future for Africa.

Advancing Africa’s Digital Agenda

As a founding partner of MWC Africa, MTN continues to value the platform’s role in listening, learning and sharing ideas to accelerate Africa’s digital transformation.

This year, our participation will be headlined by Ralph Mupita in Keynote 1: Africa’s Future First – Determining the Path to a Digital Future. The session will explore Africa’s digital transformation journey, with unique mobile subscribers projected to surpass 700 million by 2030, and examine how technologies such as AI, fintech, 5G and green innovation are reshaping industries and driving inclusive growth.

Beyond the keynote, MTN leaders will join panels and roundtables on infrastructure investment, FinTech, AI adoption, online safety, and Africa’s connected future.

An Immersive MTN Stand

Visitors to the MTN stand will experience how our platforms and innovations translate into real value for Africa’s digital future.

Together, these platforms highlight MTN’s commitment to equipping Africa for the digital economy and creating pathways to employment and innovation.

In collaboration with Ericsson, MTN will also showcase 5G-enabled applications that demonstrate the impact of real-time connectivity:

• HADO – an augmented reality game debuting in Africa, showing how low latency supports interactive learning, health and skills training
• 5G-enabled robotic dog – illustrating how connected tech enhances safety and efficiency in mining, utilities and energy
• Ray-Ban Display smart glasses – featuring neural gesture control for future possibilities in accessibility, workforce productivity and digital interactions

At the Next Generation Leaders event on October 9, held as part of WiT Singapore, four voices from across Asia’s travel ecosystem—Laura Houldsworth (Booking.com), Timothy Hughes (Agoda), Morris Sim (Montara Hospitality) and Jacinta Lim (Seek Sophie)—examined how the new travel landscape is being reshaped by artificial intelligence (AI), authenticity and the fight for trust.

The age of acceleration

Houldsworth set the tone: “The pace of change is dizzying. It’s not just planning for what happens next year, but what happens tomorrow.”

The event, sponsored by Booking.com and open by-invite to about 60 young leaders from across Asia’s online travel market, opened on how fast AI is shifting the travel equation. OpenAI, Houldsworth noted, now counts over 800 million active weekly users, a four-fold jump in less than a year.

“Except for when Taylor Swift announces something,” Houldsworth said. “I can’t think of anything that happens faster.”

But the challenge, she said, goes beyond scale, with people now searching for vibe. “How does it feel? What’s the vibe, the experience? That’s hard to put into a booking engine, that’s what will change the game.”

The funnel, unbroken but redrawn

Hughes of Agoda offered a note of grounding. “As much as technology changes, the fundamental funnel doesn’t. Someone still needs to be inspired—that’s unbreakable. What changes is who wins in each part of it.”

He recalled that in the pre-AI era, content was the loser. “Search belonged to Google. Bookings went to the OTAs. But now, with AI shifting the power of the funnel, the content question is back.”

Already, Google Gemini and OpenAI are capturing search intent in new ways. One percent of searches may not sound like much, but when you’re talking about billions, it’s enormous, the panel acknowledged.

The boardroom moment for AI

At Montara Hospitality, AI has become a standing agenda item. “Every board meeting now includes an AI update,” said Sim. “Our operations managers are all trained in it.”

For him, the question isn’t whether to use it, but how. “Distribution used to mean choosing your channels. Now, you’re expected to be in all of them and AI helps you manage that chaos.”

Yet, he added, the key is still emotion. “How do you communicate the vibe of a place? Ironically, what we put out ourselves gets the least traction. What guests create, that’s what people consume and influence.”

Trust in an age of skepticism

That trust deficit—across media, marketing and institutions—was a recurring theme. “People are skeptical. They look for multiple sources and construct their own truth,” Sim said. “AI, used well, can help aggregate those voices and even translate them into different languages.”

He recounted instances of guests saying, “ChatGPT proposed this itinerary—why isn’t it in yours?”

“It keeps us on our toes,” he said. “We have to be service-oriented but flexible. It’s less about talking about our products—we have a spa, we have a gym—but more about understanding what questions people are asking, what prompts they are using.”

The human pulse of discovery

For Lim, co-founder of Seek Sophie, the drive for experiences and authenticity hasn’t changed—only how people find it. “We started Seek Sophie because we couldn’t find the experiences we wanted online. Even on page 10 of Google, it was the same lists, same SEO.”

Her insight is clear: “People want stories, from people who’ve actually been there. They want the vibe, not a chatbot summary.”

Her comment drew nods around the room. “The more stories we tell, the more people resonate. That’s how trust builds, through voices that sound like theirs.”

Social media, she added, has become “the new luxury.”

“It’s telling people you’ve been to this place; it’s about relatability. The new aspiration is to live a story worth telling.”

Asia’s responsibility to its future

On tourism’s responsibility to the environment, Hughes shared his frustration with an airline he flew with from Bangkok to Singapore that was still giving away plastic shoehorns to its business class passengers as well as socks and eye masks on short flights. “That’s completely unnecessary.”

Lim also issued a quiet warning. “As we look at the protests going on in Europe, we in Asia have to be very careful. Our livelihoods depend on tourism assets, and we don’t have the muscle to protect these natural places. As Asia booms, what does tourism do to our natural spaces and how do we protect them?”

Responding to a question as to whether Seek Sophie could become bigger than Viator, Lim said, “If that’s the responsible thing to do, to be bigger, then yes. But growth at all costs, I don’t agree with that.”

An industry at a crossroads

Hughes brought the conversation full circle. “Sure, tech will change—AI, content, speed of development. But what we don’t yet know is how consumers will change. That’s the real unknown.”

He likened this moment to “the beginning of a monster change.”

Houldsworth added, “Even the people building the tools don’t know where this goes. All we can do is stay agile.”

The Asian moment

For Sim, this decade belongs to Asia. “Asia is shaping the global narrative now. You see Europeans, Australians, Americans coming here not just for holidays but to explore why our countries are so interesting.”

Between Japan’s inbound boom and South-east Asia’s economic rise, he said, “There’s an endless amount of opportunity in the next 50 years—as more people enter the middle class and start travelling for meaning, not mileage.”

This article originally appeared in WiT.

SEOUL — South Korea’s foreign exchange authorities on Monday issued a verbal intervention over excessive volatility in the foreign exchange market.

The Ministry of Economy and Finance and the Bank of Korea (BOK) said in a joint statement that the FX authorities are closely monitoring the possibility of herd behavior, with caution, in the process of the local currency’s expanded volatility, caused by internal and external factors.

It marked the first verbal intervention by the authorities in one and a half years since April last year when the won versus US dollar exchange rate came closer to 1,400 won per dollar amid geopolitical tensions in the Middle East.

ALSO READ: S. Korea issues verbal intervention over forex market volatility

The won versus dollar exchange rate started at 1,430.0 won, up 9.0 won compared to the previous trading day.

The rate soared to 1,434.0 won during market hours, recording the highest in five months since early May. 

By Kwanwoo Jun

  LG Electronics guided for quarterly operating profit to fall 8.4%--a smaller decline than market consensus, thanks to its key affiliates' solid performance despite tough business conditions. 

  While challenges remain from higher U.S. tariffs and a delayed recovery in global demand, its home-appliance segment maintained its competitiveness and continued to be the market leader, while its vehicle-component segment achieved record profitability, the South Korean company said Monday. 

  The consumer-electronics giant said in a preliminary earnings report that its operating profit could come in at 688.90 billion won, equivalent to $481.9 million, for the July-September period, compared with 751.90 billion won a year earlier. The projection was above a FactSet-compiled consensus estimate of 618.79 billion won. 

  Revenue is expected to have fallen 1.4% to 21.875 trillion won, LG Electronics said, also beating analysts' estimate. 

  Shares of the company rose 2% after the better-than-expected guidance, trimming its year-to-date losses to below 4%. 

  The earnings projection came as LG Electronics recently raised $1.3 billion by selling a 15% stake in its Indian unit, LG Electronics India, in an initial public offering. The company said it expects the proceeds to provide significant funding to accelerate business structure improvements and future growth initiatives. The Indian unit will begin trading Tuesday. 

  LG Electronics said it would continue its push to grow new businesses, including its heating, ventilation and air-conditioning services as well as non-hardware platforms such as appliance subscriptions and online services. 

  Analysts at Daiwa Capital said in a recent note that LG Electronics is facing business uncertainties in the second half of the year, citing a larger-than-expected U.S. tariff impact and increasing competition in the television business. The Korean company on Monday said its media and entertainment segment, which includes its TV business, experienced higher marketing costs amid intensifying global competition. 

  The company is scheduled to release its full quarterly results later this month. 

  Separately, LG Energy Solution, an electric-vehicle battery maker affiliated with the parent LG Group conglomerate, earlier forecast a 34% increase in third-quarter operating profit, surpassing market expectations. 

  The battery unit's projection of 601.30 billion won, which includes an estimated 365.50 billion won U.S. tax credit, beat a FactSet-compiled consensus forecast of 518.29 billion won. 

  Write to Kwanwoo Jun at kwanwoo.jun@wsj.com 

  (END) Dow Jones Newswires

  October 13, 2025 01:20 ET (05:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.

Introduction

Psoriasis is a chronic, immune-mediated inflammatory skin disease, with a global prevalence of approximately 2% to 3%. It is often associated with significant physical, psychological, and social burdens.¹ It typically follows a course of remission and recurrence; many patients only experience mild rash flares, but some may have a longer disease duration before receiving more intensive treatment.² The present treatment approach uses a step-up regimen—starting with topical drugs, progressing to phototherapy, and reserving systemic drugs for patients with poor control under conventional treatment.^3,4 This method minimizes overtreatment of mild disease but often delays effective systemic intervention until the disease has persisted for a longer duration. This raises the question whether early systemic treatment could yield better outcomes?

In recent years, systemic therapy, including traditional drugs such as methotrexate and acitretin, as well as biologics targeting specific inflammatory pathways, have significantly improved patients’ symptoms.^5–9 However, the response to systemic therapy varies greatly among individuals, influenced by multiple factors including disease severity, comorbidities, age of onset, treatment history, and family history.^10–12 In other chronic immune-mediated inflammatory diseases, like Crohn’s disease and rheumatoid arthritis, researchers have reported the role of disease duration on treatment response, with early use of systemic treatments leading to better clinical outcomes.^13,14 Similar to psoriasis, earlier systemic therapy may have greater advantages. However, there is still a lack of study data on the impact of disease duration on systemic therapy outcomes in psoriasis.

To our knowledge, large-scale, real-world studies specifically designed to investigate the influence of psoriasis disease duration on treatment outcomes are lacking. Previous studies have not addressed whether the duration of psoriasis affects treatment efficacy in clinical practice. Additionally, it is unclear whether the chronicity of the disease alters the efficacy of specific systemic therapies. This lack of evidence limits the development of personalized treatment strategies, particularly for patients with long-term disease.

To address this issue, this multicenter prospective observational study utilized data from the SPEECH registry to explore whether early systemic therapy truly improves clinical or patients reported outcomes. Patients with moderate-to-severe psoriasis were stratified into three groups based on disease duration at enrollment: short duration (<2 years), medium duration (2–10 years), and long duration (>10 years). Participants received various systemic therapies, including biologics, methotrexate, and acitretin. Although treatment switching may occur in clinical practice, our analyses focused on patients who maintained a single systemic therapy for at least six months, thereby ensuring reliable evaluation of treatment response. Furthermore, we examined potential contributors to disease progression, including treatment type, patient demographics, and clinical characteristics, to explore whether specific therapies were associated with greater disease stability or risk of deterioration. This study provides novel insights into the relationship between psoriasis disease course and systemic therapy efficacy in real clinical settings.

Material and Methods

Study Design

The SPEECH registry is a multicenter prospective observational study that records the clinical features of psoriasis in the Chinese population and the safety and efficacy of different treatment methods such as biologics, conventional systemic therapy, and phototherapy.¹⁵ The SPEECH registry is registered at seven dermatology centers in Shanghai, China. All data were prospectively collected at each visit using standardized case report forms and entered into a central electronic database by trained dermatology staff to ensure data completeness and accuracy. This study received ethical approval from the Institutional Review Board of Shanghai Dermatology Hospital (#2020-36), along with approvals from the ethics committees of all other participating centers.

Participants

All participants in this study are selected from the SPEECH cohort and met the following inclusion criteria: 1. Adults diagnosed with moderate-to-severe plaque psoriasis who were treated with biologic agents (such as guselkumab, ustekinumab, ixekizumab, secukinumab, or adalimumab), methotrexate, or acitretin; 2. Treatment was administered according to established protocols without modifications in dosage or treatment intervals. To ensure reliable evaluation of treatment response, only patients who remained on a single systemic therapy for at least six months were included in the analysis. Key exclusion criteria are the absence of baseline information on disease duration (Figure 1).

Figure 1 Study flowchart.

Data Collection and Outcome Measures

Demographic and clinical data were drawn from all participants at baseline, including age, gender, education level, disease duration, family history of psoriasis, BMI, lifestyle (smoking, drinking), early-onset psoriasis (age of onset <40 years), comorbidities (obesity, psoriatic arthritis, hyperlipidemia, and hypertension). To ensure consistency, treatment adherence and clinical assessments were regularly recorded and reviewed at each visit by om-site investigators.

Additionally, disease characteristics were assessed using measures such as Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), Dermatology Life Quality Index (DLQI), Physician Global Assessment (PGA), Patient Global Assessment (PtGA), Hospital Anxiety and Depression Scale – Anxiety (HADS-A) and Depression (HADS-D). Treatment efficacy was assessed at 3 months (12 weeks) and 6 months (28 weeks) after treatment, using criteria such as the PASI 75 (≥75% improvement in PASI), BSA <1/3 (clear to almost clear), PGA 0/1 (clear to almost clear), DLQI 0/1 (little to no impact on life), PtGA 0/1 (clear to almost clear), and HADS-A or HADS-D = 0 (complete resolution of anxiety or depression symptoms) at 3 months and 6 months post-treatment.

Statistical Analyses

The primary analysis used a modified intention-to-treat (mITT) dataset and employed multiple imputation to fill in the missing treatment efficacy data. By grouping patients according to disease duration (<2 years, 2~10 years, and ≥10 years). Continuous variable hypothesis Follow a normal distribution, represented by the mean (SD), and statistical comparisons are conducted using the Student’s t-test. Non-normally distributed continuous variables are represented as median (interquartile range) and compared using the Mann–Whitney U-test. Categorical variables are expressed as n (%), and analyzed using the χ2 test or Fisher’s exact probability method. Using the group with a disease duration of <2 years as a reference, logistic regression analysis was employed to evaluate the treatment response of patients with different disease durations. The adjusted odds ratio (aOR) and its 95% confidence interval (CI) were computed. To visualize response trends, line charts were generated, and intergroup differences were assessed using the Kruskal–Wallis and Dwass–Steel–Critchlow–Fligner (DSCF) tests. Additionally, subgroup analyses were performed to investigate potential interactions and factors. Sensitivity analysis was conducted based on the per-protocol (PP) dataset to further validate the robustness of the study findings. All statistical models were adjusted for potential confounders, such as gender, age, education level, early-onset psoriasis, family history of psoriasis, psoriatic arthritis (PsA), obese (BMI>28), baseline PASI, BSA score, different categories of treatment drugs, the hospital to which the patient belonged, and prior systemic therapy history. Statistical analyses were performed with R software version 4.2.2, and results with p-value <0.05 were deemed statistically significant.

Results

Clinical Characteristics According to Disease Duration

Among the initially registered 2470 patients, 1947 fulfilled the inclusion criteria for this analysis. Due to incomplete baseline information, 39 patients were excluded, leaving 1908 patients eligible for the final analysis (Figure 1). Participants were divided into three groups based on the duration of the disease: <2 years, 2~10 years, and ≥10 years. In the comparison of baseline characteristics across the three patient groups, it was noted that patients in the short disease duration group (<2 years) had more females (29.1% vs 18.3% vs 25.0%), higher education levels, more obesity (24.1% vs 19.0% vs 16.8%). In addition, patients in the short disease duration group had lower baseline PASI and BSA scores. Moreover, patients in the long disease duration group (≥10 years) were more likely to receive biologic therapy and had early-onset psoriasis (p <0.05). There were no significant differences in the remaining covariates (Table 1).

Table 1 Demographic and Patient Characteristics of the Study Cohort

Comparison of Treatment Efficacy

Using univariate logistic regression analysis to compare the efficacy outcomes among the three disease duration groups. In the unadjusted analysis, at 3 months, there were no significant differences in the proportions of the three different disease duration groups achieving BSA <1/3, PGA 0/1, PASI 75, DLQI 0/1, PtGA 0/1, HADS-A = 0, and HADS-D = 0. Even after adjusting for relevant covariates, these results remained non-significant (Table 2). Moreover, the results of the above at 6 months were similar, except that the PASI75 response rate was lower in the long disease duration group, but the adjusted OR showed no significant difference (Table 3).

Table 2 Comparison of Clinical Efficacy and Psychological Outcome of Systemic Therapy in Different Disease Duration at 3 Months

Table 3 Compare of Clinical Efficacy and Psychological Outcome of Systemic Therapy in Different Disease Duration at 6 Months

The Kruskal–Wallis and DSCF tests were used to assess intergroup differences, and line graphs were used to illustrate the changes of various treatment outcomes over time in the three groups (Figure 2). The results showed that, except for the baseline, there were almost no significant differences in the outcomes at each time point among the three groups. Moreover, all three groups exhibited downtrend of the outcomes over time, reinforcing the consistency of treatment efficacy irrespective of disease duration. This underscored the stability of systemic therapy outcomes across different disease durations.

Figure 2 Line graphs comparing treatment outcomes over time among three groups. (A) Line graphs of PSAI score and time; (B) Line graphs of BSA score and time; (C) Line graphs of DLQI score and time; (D) Line graphs of PGA score and time; (E) PASI, Line graphs of PtGA score and time. **, p<0.01; ***, p<0.001. Abbreviations: PASI, Psoriasis Area and Severity Index; BSA, Body Surface Area; DLQI, Dermatology Life Quality Index; PGA, Physician’s Global Assessment. PtGA, Patient Global Assessment.

When using PASI75 as the primary efficacy endpoint, subgroup analyses showed no significant interaction between baseline variables and disease duration categories (p for interaction >0.05; Figures S1 and S2). Similarly, no significant interaction was observed between treatment type or prior systemic therapy history and disease duration in terms of treatment outcomes, indicating that the efficacy of systemic therapy is not affected by disease duration. These results support the robustness and consistency of our primary analysis.

Sensitivity Analysis

Sensitivity analysis was also performed to verify the reliability of our results using the PP dataset. Disease duration was categorized into two groups based on the median: <15 years and ≥15 years. Both univariate and multivariate logistic regression analyses showed no significant difference in efficacy between the two groups (Tables S1 and S2). Furthermore, we conducted a hierarchical analysis according to treatment type (traditional agents vs biologics) and prior systemic therapy exposure. As presented in Tables S3 and S4, the results showed no significant differences in PASI75 response among different disease duration groups within eachstratum. The Mantel-Haenszel pooled estimates further demonstrated no significant heterogeneity across strata. The results showed that disease duration did not affect the efficacy of systemic therapies, regardless of treatment type or prior systemic therapy, supporting the robustness and consistency of our primary analysis.

Discussion

This large-scale, prospective, multicenter study provides valuable evidence on psoriasis management and treatment patterns, with patients receiving systemic therapy in routine clinical settings at seven hospitals in Shanghai, China. This study provides valuable insights into how disease duration affects clinical features and treatment outcomes of systemic therapy in Chinese psoriasis patients. Patients were divided into three groups based on disease duration: <2 years, 2–10 years, and ≥10 years. A key finding of our study is that our study showed no significant correlation between disease duration and treatment response in terms of clinical efficacy (PASI75, PGA 0/1, BSA <3) and patients reported outcomes (DLQI 0/1, PtGA 0/1, HADS-A=0, HADS-D=0) at both 3 months and 6 months. This conclusion remained robust after adjusting for relevant covariates, and sensitivity analysis further verified the reliability of the results.

We observed that patients with a short disease duration (<2 years) had higher education levels, more female patients, more obese patients, and lower baseline PASI and BSA scores. However, these characteristics did not affect the treatment outcomes. Notably, patients with a longer disease duration were more likely to receive biological therapy and present with early-onset psoriasis, both of which usually associated with increased disease severity or longer treatment exposure. This is consistent with the findings from the British Association of Dermatologists Biologic Interventions Register (BADBIR), where longer disease duration was observed with biologics compared to traditional systemic therapy (23 vs 19 years, p <0.001).¹⁶

Our findings were consistent with prior clinical studies indicating that disease duration cannot independently predict the response to systemic or biological therapy. Most available studies have focused on biologics, consistently showing that treatment response is unaffected by disease duration. For instance, a prospective cohort study of 118 patients receiving etanercept found no significant difference in PASI improvement at week 24 between between patients with disease durations <20 years versus ≥20 years (p = 0.170).¹⁷ Similarly, in another retrospective cohort study involving 135 patients receiving guselkumab, Hung et al reported no correlation between PASI 75 response and disease duration at week 36 (OR: 0.99, 95% CI 0.94–1.05), with comparable mean durations among responders and non-responders (18.42 vs 18.91 years).¹⁸ Post-hoc analysis of large RCTs, including the NAVIGATE and VOYAGE trials (n = 1678), indicated that the disease duration (<15 years vs ≥15 years) was not significantly associated with the PASI 90 response at week 40 (OR: 1.13, 95% CI: 0.88–1.47).¹⁹ Furthermore, a recent meta-analysis including 4,649 patients found that disease duration was not significantly associated with biologic treatment response (OR 0.99, 95% CI 0.98–1.00, p=0.17), reinforcing that systemic therapy efficacy is generally independent of disease duration.²⁰

Evidence regarding traditional systemic therapies is comparatively limited, but appears to suggest a similar trend. In our subgroup analyses, disease duration did not significantly influence treatment outcomes with methotrexate or acitretin. Although real-world evidence from prior studies has demonstrated the effectiveness of traditional systemic therapies in patients with moderate-to-severe psoriasis, they did not specifically evaluate whether disease duration influences treatment response. The BADBIR cohort identified predictors of reduced treatment effectiveness, including prior systemic exposure, male sex, comorbidities, and alcohol consumption, but disease duration was not among them.²¹ Similarly, a systematic review of traditional systemic therapies found no evidence that disease duration significantly modified treatment response.²² Additional analysis of treatment-switch patterns reported that disease duration did not affect the transition between traditional drugs and biologics.²³ Recent data further suggest that prior use of traditional drugs such as methotrexate or acitretin does not compromise the efficacy or drug survival of subsequent biologic therapy.²⁴ Collectively, these findings indicate that disease duration is not a major determinant of treatment outcomes for either traditional systemic agents or biologics. Importantly, prior exposure to traditional therapy does not diminish the effectiveness of subsequent biologics, thereby supporting the rationale for a step-up therapeutic strategy in clinical practice.

Although our research results indicated that early systemic therapy does not improve treatment outcomes in actual clinical settings, some studies report that early systemic treatment can actively control systemic inflammation to prevent or delay damage related to comorbidities, including psoriatic arthritis (PsA) and cardiovascular diseases.^25–29 Two different cohort studies indicated that compared to patients receiving phototherapy or topical medication, those undergoing systemic treatment have a significantly reduced risk of developing PsA.^25,26 Furthermore, new evidence suggested that biological therapy is beneficial in reversing the potential pathogenic processes of cardiovascular diseases, such as endothelial dysfunction and the progression of atherosclerotic plaques. In a large retrospective study, Song WJ et al found that compared to phototherapy, biologic therapy and non-biologic systemic therapy reduce the risk of new-onset MACE in psoriasis patients.²⁷ In order to determine whether early systemic intervention has a protective effect on psoriatic arthritis, or cardiovascular diseases, as well as whether these potential benefits make it worthwhile to upgrade treatment earlier, more long-term longitudinal studies are necessary in the future.

This study indicated that the early effectiveness of systemic therapy for psoriasis remains consistent, regardless of the disease duration, which may be related to the ability of biologics to modulate chronic inflammatory pathways and resident memory T cells in long-standing disease.^30,31 This suggests that even patients with long-standing psoriasis or delayed treatment initiation can achieve meaningful clinical responses, supporting the use of systemic therapy irrespective of disease duration.

Our research underscore that initiating systemic therapy early does not lead to better outcomes, and this observation supports the widely accepted step-up treatment strategy in current clinical practice.³² Using systemic therapy for patients with poor response to topical treatment and phototherapy reduces unnecessary systemic drug exposure and its associated costs and risks.⁴ In the absence of aggressive disease characteristics or rapid progression of joint involvement, systemic therapy may not need to be initiated immediately based solely on the disease duration. Conversely, the severity of the disease, the burden of symptoms, and the impairment of quality of life still be the main factors influencing clinical judgements. These findings provided clinical practice evidence, highlighting the importance of gradually and individually escalating systemic therapy regimens in the management of psoriasis.

It is important to recognize the limitations inherent in our study. First, like many observational studies, our analysis may be susceptible to various biases, including selection bias and unmeasured confounding factors. Second, the study cohort only included Chinese patients, which limits the generalizability of the results. Third, although a follow-up period of 6 months offers notable findings on early responses to treatment, it does not provide information on the long-term efficacy of systemic therapy or the potential effects of disease duration on outcomes such as comorbidities. Therefore, extended longitudinal follow-up is necessary to evaluate these crucial aspects.

Conclusion

Our research findings demonstrates that the short-term efficacy of systemic therapy is consistent across different disease durations, supporting the “step-up” treatment strategy in psoriasis management. This multicenter evidence adds new insights by comparing traditional agents and biologics, showing that disease duration does not alter systemic therapy response. However, emerging evidence suggests that early systemic therapy may provide long-term benefits in preventing psoriatic arthritis and major cardiovascular events. Future long-term prospective studies are needed to determine whether early systemic interventions have a protective effect on comorbidities and to refine personalized treatment plans to balance the benefits for skin and quality of life with the prevention of systemic comorbidities.

Data Sharing Statement

The dataset supporting this research can be obtained from the corresponding author upon reasonable request.

Ethics Statement

This study was approved by the medical ethics committees of the following institutions: Shanghai Skin Disease Hospital (approval No. 2020-36), Shanghai Sixth People’s Hospital (approval No.2020-KY-047K), Shanghai Changzheng Hospital (approval No.2020-27), and Shanghai Tenth People’s Hospital (approval No.20KT110). All participants provided written informed consent for the publication of their clinical data. The study was conducted in accordance with the principles of the Declaration of Helsinki.

Author Contributions

Min Dai, Yuxiong Jiang, Yujing Xi and Lezhen Xu are co-first authors. All authors made a significant contribution to the work reported, whether in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This work was sponsored by grants from the National Key Research and Development Program of China (2023YFC2508106), National Natural Science Foundation of China (No. 82430101, 82273510), Innovation Program of Shanghai Municipal Education Commission (No. 2025GDZKZD06), Shanghai Dermatology Research Center (2023ZZ02017), Clinical Research Plan of SHDC (No. SHDC22022302).

Disclosure

The authors declare no conflicts of interest.

References

1. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi:10.1016/S0140-6736(20)32549-6

2. Ma LF. Inflammatory memory in psoriasis: from remission to recurrence. J Allergy Clin Immunol. 2024;154(1):1.

3. Gisondi P, Del Giglio M, Girolomoni G. Treatment Approaches to Moderate to Severe Psoriasis. Int J Mol Sci. 2017;18(11):2427. doi:10.3390/ijms18112427

4. Chinese Society of Dermatology, China Dermatologist Association, Dermatology & Venereology Specialized Committee of Chinese Association of Integrative Medicine. Guidelines for the treatment of psoriasis with biologics and small-molecule drugs in China (2024). Chin J Dermatol. 2024;57(11):976–997.

5. Sugumaran D, Yong ACH, Stanslas J. Advances in psoriasis research: from pathogenesis to therapeutics. Life Sci. 2024;355:122991. doi:10.1016/j.lfs.2024.122991

6. Lebwohl M. Advances in biologic therapy of psoriasis. J Eur Acad Dermatol Venereol. 2023;37(9):1689–1690. doi:10.1111/jdv.19287

7. Lee HJ, Kim M. Challenges and Future Trends in the Treatment of Psoriasis. Int J Mol Sci. 2023;24(17):13313. doi:10.3390/ijms241713313

8. Alabas OA, Mason KJ, Yiu ZZN, et al. Effectiveness and survival of methotrexate versus Adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2023;189(3):271–278. doi:10.1093/bjd/ljad179

9. Armstrong AW, Pathophysiology RC. Clinical Presentation, and Treatment of Psoriasis: a Review. JAMA. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006

10. Huang D, Zhong X, Jiang Y, et al. Insulin resistance impairs biologic agent response in moderate-to-severe plaque psoriasis: insights from a prospective cohort study in China. Br J Dermatol. 2024;191(4):616–623. doi:10.1093/bjd/ljae147

11. Jiang Y, Liu X, Ma R, et al. The Impact of Family History on Clinical Presentation and Biologic Treatment Response in Patients with Psoriasis: a Multicenter Prospective Cohort Study. Am J Clin Dermatol. 2025;26(2):291–300. doi:10.1007/s40257-025-00918-y

12. Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: focus on Psoriasis Comorbidities. BioDrugs. 2023;37(1):35–55. doi:10.1007/s40259-022-00569-z

13. Deane KD, Holers VM. Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: an Emerging Paradigm Shift. Arthritis Rheumatol. 2021;73(2):181–193. doi:10.1002/art.41417

14. Berg DR, Colombel JF, Ungaro R. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25(12):1896–1905. doi:10.1093/ibd/izz059

15. Yu N, Peng C, Zhou J, et al. Measurement properties of the patient global assessment numerical rating scale in moderate-to-severe psoriasis. Br J Dermatol. 2023;189(4):437–446. doi:10.1093/bjd/ljad188

16. Iskandar IYK, Ashcroft DM, Warren RB, et al. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. Br J Dermatol. 2015;173(2):510–518. doi:10.1111/bjd.13908

17. Antoniou C, Dessinioti C, Stratigos A, Avgerinou G, Stavropoulos P, Katsambas A. Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution’s experience. J Eur Acad Dermatol Venereol. 2009;23(8):979–982. doi:10.1111/j.1468-3083.2009.03093.x

18. Hung YT, Lin YJ, Chiu HY, Huang YH. Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice. Ther Adv Chronic Dis. 2021;12:20406223211046685. doi:10.1177/20406223211046685

19. Diels J, Thilakarathne P, Cameron C, McElligott S, Schubert A, Puig L. Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis. Br J Dermatol. 2020;183(2):276–284. doi:10.1111/bjd.18634

20. Hjort G, Schwarz CW, Skov L, et al. Clinical characteristics associated with response to biologics in the treatment of psoriasis: a meta-analysis. JAMA Dermatol. 2024;160(8):830–837. doi:10.1001/jamadermatol.2024.1677

21. Warren RB, Smith CH, Yiu ZZN, et al. Effectiveness and persistence of Acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR. Br J Dermatol. 2015;172(2):337–346. doi:10.1111/bjd.13225

22. Iskandar IYK, Ashcroft DM, Warren RB, et al. Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. Br J Dermatol. 2016;174(3):606–617.

23. Tabolli S, Giannantoni P, Paradisi A, Abeni D. The ‘switcher’ patient profile in psoriasis treatment: from traditional to biological and from biological to traditional systemic drugs. Br J Dermatol. 2015;173(1):256–258. doi:10.1111/bjd.13560

24. Piaserico S, Cazzaniga S, Gisondi P, et al. “Full-naïve” patients: the impact of previous methotrexate, cyclosporine, and Acitretin on first-line biologics response in the treatment of moderate-to-severe psoriasis—a monocentric retrospective study. J Eur Acad Dermatol Venereol. 2021;35(5):e327–e330.

25. Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68–73. doi:10.1136/annrheumdis-2021-219961

26. Felquer MLA, LoGiudice L, Galimberti ML, Rosa J, Mazzuoccolo L, Soriano ER. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheumatic Dis. 2022;81(1):74–79. doi:10.1136/annrheumdis-2021-220865

27. Rosenthal YS, Schwartz N, Sagy I, Pavlovsky L. Incidence of Psoriatic Arthritis Among Patients Receiving Biologic Treatments for Psoriasis: a Nested Case–Control Study. Arthritis Rheumatol. 2022;74(2):237–243. doi:10.1002/art.41946

28. Song WJ, Oh S, Yoon HS. Association between biologic and nonbiologic systemic therapy for psoriasis and psoriatic arthritis and the risk of new-onset and recurrent major adverse cardiovascular events: a retrospective cohort study. J Am Acad Dermatol. 2025;93(1):S0190–9622(25)00524–9. doi:10.1016/j.jaad.2025.03.055

29. Reich K, Griffiths CEM, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82(4):936–945. doi:10.1016/j.jaad.2019.11.040

30. Iversen L, Conrad C, Eidsmo L, et al. Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: week 52 results from the STEPIn study. J Eur Acad Dermatol Venereol. 2023;37(5):1004–1016. doi:10.1111/jdv.18846

31. Schäkel K, Reich K, Asadullah K, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 2023;37(10):2016–2027. doi:10.1111/jdv.19236

32. Committee on Psoriasis. Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2023 edition). Chin Jl of Dermatology. 2023;56(7):573–625.

Introduction

V-pattern strabismus is one of the most common alphabetic patterns.¹ It involves a more convergent (or less divergent) horizontal deviation in downgaze than in upgaze and becomes clinically significant when vertical incomitance exceeds 15 prism diopters (Δ).²

Undoubtedly, in most cases, the V-pattern is associated with the presence of inferior oblique muscles overaction (IOOA), which leads not only to vertical and horizontal deviations but also to excyclodeviation. Excyclotorsion resulting from inferior oblique overaction is thought to contribute to the development of V-pattern strabismus by inducing extorsional displacement of the globes, thereby increasing horizontal divergence in downgaze.^3–5

Most V-patterns are, however, congenital or develop early in life, allowing suppression or anomalous retinal correspondence to prevent subjective awareness of excyclodeviation. Despite this, objective excyclotorsion in patients with V-pattern strabismus can be observed in fundus photographs, as shown in Figure 1.

Figure 1 A fundus photograph demonstrating bilateral ocular excyclotorsion in patient with bilateral inferior oblique overaction (authors own material).

Objective cyclotorsion is the measurable rotation of the eye around its visual axis, assessed using landmarks like the fovea and optic disc. The disc-foveal angle (DFA) is commonly measured via fundus photography, scanning laser ophthalmoscopy, or automated software, with studies comparing their accuracy and clinical utility.^6–9 In 2021 our team developed Cyclocheck, a web-based diagnostic tool (freely available at www.cyclocheck.com) for measuring objective cyclotorsion in both clinical and research settings and proved it to be a repeatable and reliable method for office based DFA assessment.^10,11 Figure 2 shows a screenshot of the Cyclocheck software interface.

Figure 2 Cyclocheck software interface.

Bilateral graded recession of the inferior oblique muscles effectively corrects V-pattern strabismus across varying degrees of their overaction.^12,13 It allows tailoring the surgical dosage according to IOOA severity and extent of V pattern, reducing both vertical and horizontal incomitance.^14–16 It has also been proven to have prominent incyclorotating effect in patients with various types of strabismus associated with IOOA.¹⁷ However, to the best of our knowledge, no study to date has evaluated the effect of bilateral inferior oblique graded recession on objective cyclotorsion asymmetry, specifically comparing the impact of symmetric and asymmetric surgeries.

This study aims to evaluate changes in objective cyclotorsion using Cyclocheck following bilateral graded inferior oblique recession in patients with V-pattern strabismus and inferior oblique overaction. It also aims to investigate the impact of symmetric and asymmetric surgeries on cyclotorsion asymmetry between the eyes.

Materials and Methods

This retrospective study analyzed consecutive cases of patients presenting (eso/exo) V-pattern strabismus (≥15 prism diopters difference in measurement between upgaze and downgaze) with IOOA who underwent bilateral inferior oblique muscle graded recession, with or without concurrent horizontal rectus surgery. Eligible participants demonstrated binocular vision and had no history of strabismus surgeries, including procedures on other vertically acting muscles. Informed consent was obtained from each participant. The recorded data included age, gender and the amount of V-pattern, defined as the difference between down- and upgaze. It also covered the amount of inferior oblique (IO) muscle recession in millimeters for each eye separately, the total recession for both eyes combined, and pre- and post-operative objective cyclotorsion measured by Cyclocheck using fundus photographs. Digital fundus photographs of both eyes of all study subjects were obtained using a DRS nonmydriatic fundus camera (CenterVue DRS Automatic Retinal Camera, Welch Allyn). All measurements were made before and 3 months following the surgery. Photographs were taken under binocular viewing conditions while the subject looked at an internal fixation target. A chin and forehead rest with side marks were used as a guide to ensure proper head position. The disc-foveal angle was calculated using a web-based diagnostic tool for assessing objective cyclotorsion named Cyclocheck.

The inferior oblique recession was classified as “symmetrical” when the same degree of recession was performed on both eyes, provided the vertical deviation in the primary position was less than 5 prism diopters. If hypertropia ranged from 5 to 10 prism diopters, the recession in the more hypertropic eye was increased by 2 mm; for 10 to 15 prism diopters, by 4 mm; and for 15 or more prism diopters, by 6 mm. The amount of inferior oblique muscle recession was determined based on the severity of overelevation in adduction: +1 IOOA corresponded to 8 mm of recession, +2 IOOA to 10 mm, +3 IOOA to 12 mm, and +4 IOOA to 14 mm.

All procedures performed in studies involving human participants conformed to all local laws and were by the ethical standards of the Bioethical Committee of the Medical University in Lodz, Poland and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Bioethical Committee of the Medical University in Lodz, Poland (RNN/260/23/KE).

Statistical Analysis

Comparisons were made using paired t-test and Wilcoxon signed-rank test. Normality of data distribution was assessed using the Shapiro–Wilk test. Paired t-tests were used for normally distributed variables, while non-normally distributed variables were analyzed using the Wilcoxon signed-rank test. Correlations between the variables were evaluated using the Pearson correlation coefficient (r). A Fisher’s z-test was used to examine the difference between two correlation coefficients. Statistical analysis was conducted using Python (Python Software Foundation, Netherlands). A p-value of ≤ 0.05 was considered statistically significant.

Results

A total of 50 patients (100 eyes) were included in the study. The gender distribution was comparable, with 26 females and 24 males. The mean age was 10.46 years. V-pattern esotropia was observed in 22 patients (44%), and exotropia in 28 patients (56%). All the patients enrolled in the study underwent uneventful bilateral inferior oblique muscle graded recession of 8, 10, 12 and 14 mm as detailed in the methodology section. The procedure was symmetrical in 21 cases and asymmetrical in 29 cases (22 by 2 mm, 5 by 4 mm and 2 by 6 mm). The mean inferior oblique recession in millimeters was 10.92±1.81 in the right eye and 10.92±1.94 in the left eye, with the bilateral absolute amount of 21.84±3.04. The amount of V-pattern decreased significantly in all cases, but a residual V-pattern was observed in 4 cases (8%) – 5-10 PD of vertical incomitance in 3 cases and 25PD in one case (the patient had preoperative V-pattern of 50PD). Clinical characteristics of the study participants are presented in Table 1.

Table 1 Clinical Characteristics of the Study Participants

A positive correlation was observed between the preoperative amount of V-pattern and preoperative absolute objective cyclotorsion (r=0.36, p=0.0093). This was no more valid postoperatively when absolute objective cyclotorsion had a light negative correlation with remnant V-pattern (r= −0.09, p=0.0001). A positive correlation was observed between the amount of IO recession and the change in absolute objective cyclotorsion (r = 0.46, p = 0.00), as shown in Figure 3. The mean reduction of objective cyclotorsion was 2.52° of cyclotorsion/ per 2 mm of recessed inferior oblique muscle. As shown in Figure 4, the total change of absolute objective cyclotorsion was moderately correlated with the reduction of the V-pattern (r=0.38, p=0.0032).

Figure 3 The correlation between the amount of inferior oblique recession and change in absolute objective cyclotorsion.

Figure 4 The correlation between the total change in absolute objective cyclotorsion and the reduction of the V-pattern.

A linear relationship was observed between the amount of inferior oblique recession in each eye separately and the change in objective cyclotorsion of the respective eye (right eye: r=0.37, p=0.0083; left eye: r=0.37, p=0.0087). The correlations were less evident than the one for both eyes, but they did not differ significantly (Fisher’s z-test 0.72 p=0.47). There was a positive correlation between the amount of preoperative objective cyclotorsion and the surgically induced change in objective cyclotorsion for each separate eye (Wilcoxon signed-rank test z= 6.452, p= <0.0001, Paired t test t= 5.1309, df= 54, p= <0.0001).

We also examined symmetric and asymmetric surgeries to assess their impact on cyclotorsion asymmetry between the eyes. Overall, the mean cyclotorsion asymmetry was significantly lower postoperatively (preoperative: 5.50°±3.40° vs postoperative: 4.00°±3.00°, p<0.001). However, this was independent of whether the surgery was symmetric or asymmetric. The influence on the amount of cyclotorsion asymmetry was similar in both groups (RE/LE difference: symmetric group 1.55°±4.15° and asymmetric group 1.47°±3.30°; p=0.938).

Discussion

Inferior oblique overaction (IOOA) and associated V-pattern strabismus present significant challenges in strabismus management, often requiring surgical intervention to restore ocular alignment and minimize torsional deviations. Our study contributes to the growing body of evidence supporting graded inferior oblique recession as an effective approach for reducing both objective cyclotorsion and V-pattern deviation.^14,17,18

Multiple studies have investigated the effect of inferior oblique muscle weakening procedures on ocular torsion. As early as 1986, Kushner, in his research evaluating cyclotorsional effects, noted that weakening the inferior oblique or tightening the superior oblique resulted in long-term incyclorotation (clockwise for right eyes and counterclockwise for left eyes) of the axis of astigmatism by approximately 10°.¹⁹ Sharma et al²⁰ compared Fink’s recession with modified Elliot and Nankin’s anteropositioning, both of which resulted in a comparable degree of intorsional shift (+2.5° and +4.7°, respectively), with no statistically significant difference between the two techniques. The mean preoperative extorsion was 9.8° in patients undergoing Fink’s recession and 11.4° in those undergoing modified Elliot and Nankin’s anteropositioning. A study by Farid et al²¹ evaluated the effect of inferior oblique anterior transposition (IOAT) on fundus torsion and detected significant decrease from 12.67±8.13° preoperatively to 3.40±5.06° postoperatively. Sethi et al¹⁷ compared various inferior-oblique weakening procedures achieving mean reduction in excyclotorsion 3.65° in group treated with inferior oblique recession.

The mean preoperative objective cyclotorsion in our study was 13.48°±6.36° in the right eye and 11.50°±6.71° in the left eye, consistent with the expected presence of excyclotorsion in patients with V-pattern strabismus and inferior oblique overaction.^22–24 Notably, the mean disc-foveal angle (DFA) reported by Sethi et al¹⁷ for patients undergoing inferior oblique weakening for primary or secondary inferior oblique overaction was 11.52°±7.15°, a value closely aligning with our findings, further supporting the reproducibility of these measurements in similar patient populations. Similarly, a study by Lee et al¹⁸ investigating objective excyclotorsion following graded inferior oblique recession in patients with primary and secondary inferior oblique overaction (IOOA) reported a mean preoperative torsional angle of 13.25°±6.74° in patients with primary IOOA and 16.91°±7.57° in those with secondary IOOA.

A moderate positive correlation was found between the preoperative amount of V-pattern and absolute objective cyclotorsion (r=0.36, p=0.0093). However, postoperatively, this relationship was no longer observed, as absolute objective cyclotorsion showed a slight negative correlation with the remaining V-pattern (r= −0.09, p=0.0001), showing that V-pattern improvement is largely independent of the degree of torsional correction. A possible explanation for this result is that the surgical correction of the V-pattern strabismus and inferior oblique overaction disrupted the preoperative relationship between the magnitude of the V-pattern and objective cyclotorsion. Postoperatively, as the V-pattern was significantly reduced, the remaining variation in cyclotorsion may have been influenced by other factors, such as individual differences in muscle elasticity, neural adaptation, or residual oblique muscle function. Additionally, the slight negative correlation could suggest a compensatory mechanism, where some patients with minimal residual V-pattern exhibited greater postoperative cyclotorsion adjustments due to neural adaptation or changes in extraocular muscle dynamics. These mechanisms were examined in the study by Schworm et al, which analyzes the underlying factors contributing to the well-documented long-term postoperative subjective cyclotorsional changes.²⁵

Following surgery, our study population showed a significant reduction in objective cyclotorsion (right eye: 5.99°±4.50°; left eye: 8.39°±3.82°), ultimately aligning closely with the levels observed in normal subjects. The average disc-foveal angle, as reported in the literature and confirmed by our previous research, typically ranges between 5° and 7.5°.^7,11,26–29

The average excyclotorsion reduction observed in our study population was 2.52° for every 2 mm of inferior oblique muscle recession. These results are consistent with Harada et al³⁰ estimated a 1° change for every 1 mm of recessed inferior oblique muscle. Lee et al¹⁸ reported Lee et al¹⁸ reported a statistically significant change in cyclorotation, but did not establish a correlation between the degree of recession and the change in cyclorotation, making it impossible to directly relate our results to his findings.

Moreover, we observed a positive correlation between the amount of inferior oblique recession and the change in absolute objective cyclotorsion (r=0.46, p=0.00), indicating that greater recession generally resulted in a more significant reduction in cyclotorsion. A similar observation was made by Sethi et al.¹⁷ A linear relationship was also detected when analyzing each eye separately, with similar correlation coefficients for the right (r=0.37, p=0.0083) and left eye (r=0.37, p=0.0087). Although these correlations were slightly weaker when considering both eyes together, the difference was not statistically significant (Fisher’s z-test 0.72, p=0.47). This suggests that while inferior oblique recession influences cyclotorsion at the individual eye level, the overall binocular effect remains consistent, reinforcing the effectiveness of this procedure in managing torsional misalignment.

Interestingly, we found a positive correlation between preoperative objective cyclotorsion and the change in postoperative objective cyclotorsion in each eye. This suggests that the eye with greater preoperative excyclotorsion undergoes a greater change in objective cyclotorsion following surgery. Our results align with those of Sethi et al¹⁷ who suggested that, at the pooled data level, this correlation might partly stem from the graded approach to inferior oblique weakening. In this approach, the choice of surgical procedure depends on the degree of inferior oblique overaction and the V pattern, with more powerful weakening procedures typically performed in eyes with greater baseline excyclotorsion. Additionally, they propose a possible “self-adjusting” mechanism in inferior oblique weakening procedures, in which the degree of preoperative excyclotorsion influences postoperative changes in excyclotorsion, regardless of the final anatomical position of the inferior oblique – an idea that warrants further examination.

We observed a significant reduction in the mean V-pattern, decreasing from 18.62Δ±9.77Δ to 2.26Δ±5.76Δ(p<0.0001). Sethi et al¹⁷ also reported a significant reduction in V-pattern, from 19.20Δ±6.31Δ to 6.45Δ±4.05Δ. However, these values represent all procedures evaluated in their study (including inferior oblique recession, recession and anteropositioning, anterior transposition, and anterior and nasal transposition), making direct comparison with our results difficult.

The procedure demonstrated a high success rate, with complete resolution of the V-pattern in 46 cases included in our study, accounting for 92% of the study population. The total change of absolute objective cyclotorsion was moderately correlated with the reduction of the V-pattern (r=0.38, p=0.0032). Taken together, these results support the role of graded inferior oblique muscle recession as an effective surgical option for the management of V-pattern strabismus. As stated in the introduction, no study to date has assessed the effect of bilateral inferior oblique graded recession on cyclotorsion asymmetry, particularly in terms of comparing the impact of symmetric and asymmetric surgeries. Postoperatively, we observed a significant reduction in cyclotorsion asymmetry between the eyes. However, our analysis detected that this reduction occurred regardless of whether the surgery was performed symmetrically or asymmetrically. Both surgical approaches demonstrated a comparable impact on cyclotorsion asymmetry, with the RE/LE difference measuring 1.55°±4.15° in the symmetric group and 1.47°±3.30° in the asymmetric group (p=0.938).

A study by Yilmaz et al³¹ examined the effects of unilateral and bilateral inferior oblique myectomy (IOM) on fundus torsion in patients with primary and secondary IOOA. Their findings demonstrated that bilateral IOM significantly reduced both the mean disc-foveal angle (DFA) and DFA asymmetry between the eyes across all patient groups. However, due to the fact that with this procedure, the remaining muscle is released freely into the Tenon’s capsule, the exact location where the muscle will reattach is unpredictable and thus difficult to compare among patients. This is why, direct comparison of the above-mentioned study with our results is limited.

Undoubtedly, our findings suggest that the symmetry of the procedure is not a determining factor in postoperative cyclotorsion alignment. Instead, other factors may play a more significant role in the observed improvements, highlighting the need for further investigation.

Possible limitation of our study is the retrospective design of this study, which may have led to potential bias in establishing causation. Additionally, the follow-up period was limited to 3 months, which may not capture long-term changes in cyclotorsion; however, based on our clinical experience and previous observations, the effect appears to be long-lasting. The relatively small sample size without a formal power analysis may limit the reliability of subgroup findings. An additional limitation of this study is that concurrent horizontal rectus muscle surgery was performed in some patients, which may have acted as a confounding factor and influenced the postoperative changes in ocular alignment or cyclotorsion.

Conclusion

Graded inferior oblique muscle recession is an effective surgical technique for reducing objective cyclotorsion and V-pattern deviation. Our findings demonstrate a significant correlation between the total amount of muscle recession and the overall change in absolute cyclotorsion. However, changes in cyclotorsion of individual eyes were not reliably predicted by the amount of recession in each eye. Additionally, postoperative reduction in interocular cyclotorsional asymmetry occurred regardless of whether the surgery was performed symmetrically or asymmetrically.

Acknowledgments

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Disclosure

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

1. Zhu B, Wang X, Fu L, Yan J. Pattern strabismus in a tertiary hospital in Southern China: a retrospective review. Medicina. 2022;58(8):1018. doi:10.3390/medicina58081018

2. Saxena R, Dhiman R. Pattern strabismus. American academy of ophthalmology. Available from: https://www.aao.org/disease-review/pattern-strabismus. Accessed September 13, 2022.

3. Knapp P. Vertically incomitant horizontal strabismus, the so-called A and V syndromes. Trans Am Ophthalmol Soc. 1959;57:666.

4. Phillips PH, Hunter DG. Evaluation of ocular torsion and principles of management. In: Rosenbaum AL, Santiago AP, editors. Clinical Strabismus Management, Principles and Surgical Techniques. Philadelphia: WB Saunders; 1999:52–72.

5. Guyton DL. Ocular torsion: sensorimotor principles. Graefes Arch Clin Exp Ophthalmol. 1988;266(3):241–245. doi:10.1007/BF02181189

6. Jonas RA, Wang YX, Yang H, et al. Optic disc – fovea angle: the Beijing eye study. PLoS One. 2015;10(11):e0141771. doi:10.1371/journal.pone.0141771

7. Vélez Escolà L, Galán Terraza A, Lagrèze WA, et al. Disc-foveal angle and ocular counterrolling as a key in its interpretation. Arch Soc Esp Oftalmol. 2019;94(12):585–590. doi:10.1016/j.oftal.2019.05.019

8. Kanku MS, Sele S, Held U, et al. Cyclotorsion measurement on scanning laser ophthalmoscopy imaging compared with fundus photography in patients with fourth nerve palsy and healthy controls: cySLO-IV study. J Neuroophthalmol. 2012;41(4):e612–e618. doi:10.1097/WNO.0000000000000996

9. Jethani J, Dave P. A technique for standardizing disk foveal angle measurement. J AAPOS. 2015;19(1):77–78. doi:10.1016/j.jaapos.2014.08.015

10. Simiera J, Loba P. Cyclocheck: a new web-based software for the assessment of objective cyclodeviation. J AAPOS. 2017;21(4):305–308. doi:10.1016/j.jaapos.2017.02.009

11. Simiera J, Ordon AJ, Loba P. Objective cyclodeviation measurement in normal subjects by means of Cyclocheck^® application. Eur J Ophthalmol. 2021;31(2):704–708. doi:10.1177/1120672120905312

12. Sokeer SH, Caldeira JA. V-pattern esotropia: a review; and a study of the outcome after bilateral recession of the inferior oblique muscle: a retrospective study of 78 consecutive patients. Binocul Vis Strabismus Q. 2023;18(1):35–48.

13. Caldeira JA. Some clinical characteristics of V-pattern exotropia and surgical outcome after bilateral recession of the inferior oblique muscle: a retrospective study of 22 consecutive patients and a comparison with V-pattern esotropia. Binocul Vis Strabismus Q. 2004;19(3):139–150.

14. Sokeer SH, Ali AL, Arafa ES, Awara AM, Shafik HM. Evaluation of graded recession of inferior oblique muscle for correction of different grades of V-pattern strabismus. BMC Ophthalmol. 2023;23(1):462. doi:10.1186/s12886-023-03210-x

15. Mostafa AM, Kassem RR. Comparative study of unilateral versus bilateral inferior oblique recession/anteriorization in unilateral inferior oblique overaction. Eur J Ophthalmol. 2017;28(3):272–278. doi:10.5301/ejo.5001062

16. Huang YT, Chen JJ-Y, Wu M-Y, et al. The effects of modified graded recession, anteriorization and myectomy of inferior oblique muscles on superior oblique muscle palsy. J Clin Med. 2021;10(19):4433. doi:10.3390/jcm10194433

17. Sethi A, Dhiman R, Mahalingam K, et al. Evaluation of change in objective cyclotorsion after various inferior oblique-weakening procedures. J AAPOS. 2023;27(6):345. doi:10.1016/j.jaapos.2023.08.016

18. Lee D, Kim WJ, Kim MM. Comparison of excyclotorsion following graded inferior oblique recession for primary versus secondary inferior oblique overaction. Int J Ophthalmol. 2020;13(8):1281–1286. doi:10.18240/ijo.2020.08.15

19. Kushner BJ. The effect of oblique muscle surgery on the axis of astigmatism. J Pediatr Ophthalmol Strabismus. 1986;23(6):277–280. doi:10.3928/0191-3913-19861101-05

20. Sharma P, Thanikachalam S, Kedar S, Bhola R. Evaluation of subjective and objective cyclodeviation following oblique muscle weakening procedures. Indian J Ophthalmol. 2008;56(1):39–43. doi:10.4103/0301-4738.37594

21. Farid MF, Sherin Bayoumy A, Seada M. Changes in fundus torsion following anterior transposition surgery of the inferior oblique muscle. BMFJ. 2023;40(surgical issue):55–67.

22. Cho SY, Lee SY, Lee CY. Clinical evaluation of excyclotorsion in patients with primary inferior oblique overaction. J Korean Ophthalmol Soc. 2012;53(9):1324–1329. doi:10.3341/jkos.2012.53.9.1324

23. Na KS, Lee SY, Lee YC. Ocular torsion in unilateral superior oblique palsy. J Korean Ophthalmol Soc. 2007;48(10):1388. doi:10.3341/jkos.2007.48.10.1388

24. Kushner BJ. A”, “V”, and other alphabet pattern strabismus. In: Taylor D, Hoyt CS, editors. Pediatric Ophthalmology and Strabismus. 3rd ed. London: Elsevier Saunders; 2005:922–931.

25. Schworm HD, Eithoff S, Schaumberger M, Boergen KP. Investigations on subjective and objective cyclorotatory changes after inferior oblique muscle recession. Invest Ophthalmol Vis Sci. 1997;38(2):405–412.

26. Lengwiler F, Rappoport D, Jaggi GP, Landau K, Traber GL. Reliability of cyclotorsion measurements using scanning laser ophthalmoscopy imaging in healthy subjects: the CySLO study. Br J Ophthalmol. 2018;102(4):535–538. doi:10.1136/bjophthalmol-2017-310396

27. Williams TD, Wilkinson JM. Position of the fovea centralis with respect to the optic nerve head. Optom Vis Sci. 1992;69(5):369–377. doi:10.1097/00006324-199205000-00006

28. Bixenman WW, von Noorden GK. Apparent foveal displacement in normal subjects and in cyclotropia. Ophthalmology. 1982;89(1):58–62. doi:10.1016/S0161-6420(82)34862-9

29. Miyata M, Yoshikawa M, Ohtsuki H, et al. Age-related change and sex difference over 60s in disc-fovea angle in Japanese population: the Nagahama Study. Acta Ophthalmol. 2018;96(7):840–845. doi:10.1111/aos.13642

30. Harada M, Ito Y. Surgical correction of cyclotropia. Jpn J Ophthalmol. 1960;8:88–96.

31. Yilmaz OF, Oguz H. Evaluation of the effect of unilateral and bilateral inferior oblique myectomy on fundus torsion in primary and secondary inferior oblique overaction. North Clin Istanb. 2023;10(5):657–665. doi:10.14744/nci.2023.74875

Introduction

Osteoarthritis (OA) is a primary cause of disability and chronic pain, impacting approximately 500 million people worldwide, with forecasts of almost one billion by 2050.^1,2 OA considerably lowers the quality of life due to its characteristic progressive joint deterioration, pain, and loss of mobility. Though they provide short-term comfort, non-steroidal anti-inflammatory medicines (NSAIDs) and corticosteroids present significant gastrointestinal, cardiovascular, and renal hazards when used long-term.^3,4 While effective for some, surgical interventions are invasive, costly, and not universally accessible.

These restrictions have fueled a rise in interest in integrative and alternative treatments. The monosodium iodoacetate (MIA) model has been a valuable instrument for reproducing important OA characteristics in preclinical research. Therefore, it is a promising avenue for assessing new, non-pharmacologic treatments.^5,6 The GB34 acupoint, located near the fibular head, is often used for joint-related indications in both experimental and clinical settings. Evidence suggests that stimulation at GB34 can modulate inflammatory processes and promote cartilage preservation.^7–9

Acupuncture has gained recognition for its affordability,¹⁰ safety,^11,12 and effectiveness in managing musculoskeletal pain. The American College of Rheumatology conditionally recommends it for knee OA,¹³ with reviews supporting its pain-relieving and functional benefits.^14–17 Acupuncture treatments such as Electroacupuncture (EA), bee venom acupuncture (BVA), and laser acupuncture (LA) differ in mechanism while sharing common targets. Although previous studies have noted the therapeutic benefits of LA, EA, and BVA in OA.^18–23 This study is the first to directly compare these treatments under the same conditions. This direct comparison fills a critical gap in the literature, providing valuable insights for clinical decision-making in integrative pain management. The potential impact of these findings on the future of pain management is significant.

Methods

Ethics Statement

This study was approved by the Dongshin University Animal Committee (DSU-2024-07-04). All animal care and experiments were conducted under the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and Dongshin University Institutional Animal Care and Use Committee policies.

Animals and Osteoarthritis Induction

Forty-eight male Sprague-Dawley rats (8 weeks old, 240–280 g; SAMTAKO Korea) were housed under controlled conditions (22 ± 2°C, reversed 12-hour light/dark cycle) with ad libitum access to food and water.

Male rats were used to reduce differences in pain and inflammatory responses caused by sex hormones. This decision was based on previous research showing that pain from OA varies significantly with a rat’s age and sex.²⁴

OA was induced via intra-articular injection of monosodium iodoacetate (MIA; Sigma-Aldrich, St. Louis, MO). MIA was dissolved in 30 μL of sterile saline at 1 mg. Under brief isoflurane anesthesia, the injection was administered into the medial side of the patellar ligament of both knees using a 19-gauge, 0.5-inch needle, ensuring the needle did not penetrate the cruciate ligaments. The control group received an equivalent volume of sterile saline. Post-injection, the limbs were gently massaged before returning the rats to their housing.

Experimental Groups

Rats were randomly assigned to six groups (n = 8 per group): Control (Con): No OA induction or treatment. OA: MIA-induced OA without treatment. Manual Acupuncture (MA): MIA-induced OA treated with manual acupuncture at GB34. Invasive Laser Acupuncture 830nm (830nm): MIA-induced OA treated with 830nm invasive laser acupuncture at GB34. Electroacupuncture (EA): MIA-induced OA treated with Electroacupuncture at GB34. Bee Venom Acupuncture (BVA): MIA-induced OA treated with bee venom acupuncture at GB34.

Acupuncture Treatments

All acupuncture treatments commenced one-week post-MIA injection and were administered three times per week for four weeks.

Manual Acupuncture (MA): Sterile acupuncture needles (0.25 mm diameter, 13 mm length) were inserted bilaterally at GB34 to a depth of approximately 5 mm. Needles were manually stimulated with gentle twirling for 30 seconds every minute during a 3-minute session.

Invasive Laser Acupuncture 830nm: Using the Ellise device (Wontech Co. Ltd., Daejeon, Republic of Korea), an optic fiber-coupled laser diode was inserted into sterile acupuncture needles. The laser was set at 50Hz, 20mW, and applied for 3 minutes per session at GB34 on both legs to a depth of 5 mm.

Electroacupuncture (EA): Sterile stainless-steel acupuncture needles (0.25 mm diameter, 13 mm length) were inserted bilaterally at GB34 to a depth of approximately 5 mm. Electrical stimulation was applied using a constant current EA device, delivering alternating frequencies of 2/10 Hz at an intensity of 1 mA for 3 minutes per session.

Bee Venom Acupuncture (BVA): A 0.1 mL injection of bee venom solution (1.0 mg/mL) was administered subcutaneously at GB34 using a 30-gauge insulin syringe to a depth of approximately 5 mm.

Behavioral Assessment

Joint pain severity was assessed using the paw withdrawal threshold (PWT) test with manual von Frey filaments. Rats were acclimatized for 10 minutes in individual boxes. A filament with a bending force of 0.6 g was applied perpendicularly to the plantar surface of each hind paw until it bent slightly, and the response was recorded. If no response was observed, a filament with the next higher force was used; if a response occurred, the next lower force was applied. This up-down method continued until a pattern of responses allowed for calculating the 50% withdrawal threshold. Each paw was tested three times, with a 3-minute interval between tests. The mean values were used for statistical analysis. PWT assessments were conducted before MIA induction and weekly thereafter for four weeks.

Behavioral and structural outcomes were assessed up to 4 weeks post-MIA and treatment, a time window known to capture pain progression, early cartilage, and bone alterations in MIA-induced OA models.^25,26

Micro-Computed Tomography (Micro-CT) Imaging

After the treatment period, the rats were euthanized using a carbon dioxide (CO₂) gas chamber via a gradual-fill method, following the AVMA Guidelines for the Euthanasia of Animals (2020 Edition). This approach ensured a humane endpoint, minimizing pain and distress. The right knee joints were harvested, fixed in 4% paraformaldehyde, and subjected to micro-CT scanning using the Quantum GX2 imaging system. Data were analyzed using AccuCT™ software (PerkinElmer).

Histological Analysis

Following micro-CT scanning, knee joint tissues were decalcified in 0.5M ethylenediaminetetraacetic acid (EDTA, pH 8.0) for twentyone days, with the solution changed every two to three days. After decalcification, tissues were dehydrated through a graded ethanol series, cleared in xylene, and embedded in paraffin wax. Paraffin blocks were sectioned sagittally at nine μm thickness using a microtome. Safranin O/fast green staining was used to assess cartilage integrity. The severity of osteoarthritis was evaluated using the Osteoarthritis Research Society International (OARSI) scoring system and the Mankin score.

Statistical Analysis

Data were analyzed using R software (version 4.3.2) and presented as mean ± standard deviation (SD). Data was assessed for normality using the Shapiro–Wilk test, and a parametric method was applied. Comparisons between groups were made using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test for multiple comparisons. A p-value < 0.05 was considered statistically significant.

Results

Acupuncture Therapies Progressively Alleviate Pain Behaviors in MIA-Induced OA Rats

Paw withdrawal thresholds (PWT) were monitored over time to assess acupuncture’s impact on mechanical allodynia. Before MIA-injection, all groups exhibited similar baseline PWTs (15.2±0.9g), confirming no pre-existing differences. One-week post-MIA induction, all groups showed a rapid and sustained reduction in PWT, confirming pain hypersensitivity (Figure 1A) while the control group remained stable Acupuncture-treated rats showed progressive recovery. By Week 2, EA and LA groups showed modest improvements (p < 0.05; p<0.01 vs OA) while MA and BVA groups did not show any significant improvement. From Week 3 onward, LA and EA exhibited further gains (p < 0.01), with all three modalities demonstrating significant pain reversal by the final week (LA: p < 0.001; EA: p < 0.01; MA: p < 0.05). Weekly comparisons revealed that LA maintained a significant reduction from week two onwards, EA was improved on week two and four and MA started showing improvement from week four (Figure 1B).

Figure 1 Changes in paw withdrawal threshold over 4 weeks across different treatment groups in MIA-induced OA rats. (A) Changes in paw withdrawal threshold over time. (B) PWT values for groups from Week_1 to Week_4; n=8 per group. Data are presented as the mean ±standard deviation; p<0.05, p <0.05, p <0.01, p <0.001 compared with the OA group. Abbreviations: Con, control; OA, osteoarthritis; BVA, bee venom acupuncture; MA, manual acupuncture; EA, electro-acupuncture; LA, laser acupuncture.

Micro-CT Imaging Demonstrates Joint Preservation and Inhibition of Pathological Ossicle Formation

Micro-CT imaging revealed that untreated OA knees displayed classic signs of joint degeneration: subchondral erosion, trabecular irregularity, and surface damage (Figure 2). In contrast, the EA, LA, and BVA groups maintained better joint morphology, smoother bone contours, and preserved trabeculae.

Figure 2 Representative micro-CT 3D images. The control knee maintains trabecular subchondral plate integrity with a smooth contour; the OA knee exhibits clear bone erosion following MIA induction. n=8. Abbreviations: Con, control; OA, osteoarthritis; BVA, bee venom acupuncture; MA, manual acupuncture; EA, electro-acupuncture; LA, laser acupuncture.

Meniscal ossicles, indicative of OA progression, were significantly enlarged in OA rats (Figure 3). LA significantly reduced ossicle volume and area (p < 0.006 and p < 0.006 vs OA). EA, BVA and MA groups exhibited moderate effects.

Figure 3 Micro-CT analysis of the hind knee joint in MIA-induced OA rats; (A) Area, (B) Volume of the meniscal ossicles. The area and volume of meniscal ossicles, abnormal bone formations within the knee meniscus, across different groups compared to the OA group. Error bars represent standard deviation. p-values indicate significant differences compared to the OA group. n=8. Data are presented as the mean ±standard deviation; p <0.05, p <0.01, p <0.001. Abbreviations: Con, control; OA, osteoarthritis; BVA, bee venom acupuncture; MA, manual acupuncture; EA, electro-acupuncture; LA, laser acupuncture.

Laser and Electroacupuncture Preserve Cartilage Integrity

Safranin-O/Fast Green staining revealed severe cartilage erosion, proteoglycan loss, and chondrocyte disarray in OA rats (Figure 4). EA and LA groups retained matrix staining and structural integrity, similar to the control group. BVA and MA showed partial preservation.

Figure 4 Histological images and quantification of cartilage degradation using Safranin-O/Fast Green staining. (A) Sagittal sections of rat knee joints from each group were stained with Safranin-O/Fast Green. Red staining indicates proteoglycan-rich cartilage, while loss of staining denotes matrix degradation. The OA group showed severe cartilage erosion and proteoglycan loss, whereas the EA and LA groups retained staining patterns similar to the control. Upper row: 10× magnification (scale bars = 100 µm); Lower row: 20× magnification (scale bars = 50 µm). (B) Quantitative assessment of cartilage damage using a modified OARSI scoring system. Boxplots represent median and interquartile range, with individual data points shown. EA and LA groups exhibited significantly lower cartilage scores compared to the OA group (****p < 0.0001, ***p < 0.001, **p < 0.01; one-way ANOVA with Tukey’s post hoc test). Groups with different letters differ significantly, while groups that share a letter do not differ significantly (a-d) (p < 0.05). Abbreviations: Con, control; OA, osteoarthritis; BVA, bee venom acupuncture; MA, manual acupuncture; EA, electro-acupuncture; LA, laser acupuncture.

Quantitative scoring confirmed these findings (Figure 4). OA rats had significantly elevated cartilage damage scores (ANOVA, p < 2.2e−16). EA and LA had the lowest scores (p < 0.0001 vs OA), while BVA and MA showed intermediate reductions (p < 0.001, p < 0.01, respectively).

Discussion

Pain is often the earliest and most persistent symptom of OA, so this study focused on it. We set out to investigate whether EA, LA, and BVA could relieve pain and slow the progression of joint degeneration in MIA-induced OA rats. The results of our study not only confirm the potential of these acupuncture therapies and offer hope and optimism for the future of OA treatment.

Behaviorally, LA and EA improved pain thresholds by Week 2, and by Week 4, LA, EA, and MA significantly reversed mechanical hypersensitivity. Animals in the BVA group experienced some inflammation at the acupoint after treatment; this could account for the low PWT. These effects were verified by micro-CT findings, which showed preserved subchondral structure in EA and LA groups. Rarely assessed in preclinical acupuncture studies, ossicle formation was markedly inhibited by EA and LA, suggesting modulation of aberrant bone remodeling. Safranin-O staining further confirmed that EA and LA most effectively preserved cartilage integrity.

Previous studies have individually validated the efficacy of acupuncture treatments. For instance, Ma et al showed that early EA (at ST35/ST36) preserved cartilage and relieved pain, while delayed EA had reduced benefit.²⁷ Chen et al further revealed that EA acts via sympathetic β2-adrenergic signaling to suppress IL-6, reduce synovial inflammation, and ameliorate pain behaviors.²² Our results align with these findings, as EA improved PWT threshold by week 2 and preserved cartilage, as confirmed by the histology scores.

LA has shown promise in modulating inflammation and promoting cartilage repair.^21,28 Li et al demonstrated that 10.6 μm infrared LA reduced MMP-13 expression, improved weight-bearing, and preserved cartilage in MIA-OA rats, resulting in LA’s anti-inflammatory and chondroprotective potential.²⁹ In our study, invasive 830 nm LA produced similar benefits: pain thresholds improved significantly from Week 2, cartilage histology closely resembled that of the control group by Week 4 and reduced ossicle formation. These results suggest that LA, despite being a less invasive and more technologically modern modality, may offer outcomes comparable to EA in treating OA as the LA penetrates deeper into the skin.³⁰

 BVA has demonstrated significant analgesic and anti-inflammatory effects through pharmacological mechanisms. Chen and Larivière (2010) reviewed bee venom’s actions and noted its impact on opioid receptors and the suppression of proinflammatory cytokines such as TNF-α and IL-1β.³¹ Our study supports this mechanistic framework as BVA-treated rats exhibited early pain relief (Week 2) and moderate histological protection. However, its structural preservation was less pronounced than that observed with EA and LA.

A subset of rats in the BVA group developed localized swelling and reduced mobility following the initial bee venom injections. Such responses are consistent with documented side effects of bee venom therapy, which include local inflammation, edema, and, in some cases, systemic reactions. For instance, a systematic review highlighted that bee venom therapy can lead to adverse events ranging from mild local reactions to severe systemic responses, depending on the dosage and administration method. Additionally, studies have reported that bee venom injections can cause localized swelling and pain in animal models. These adverse reactions were not observed in the other treatment groups.^32,33

Our findings align with a network meta-analysis by Corbett et al (2013), which found acupuncture among the most effective non-pharmacological treatments for knee OA.¹⁶ While their analysis was limited to clinical studies and did not distinguish between acupuncture types, our data add nuance by suggesting that different modalities may yield comparable overall benefits through distinct mechanisms.

Few studies have directly compared EA and LA. Kim et al (2019) evaluated EA and LA in a collagenase-induced arthritis model and reported superior outcomes with LA.²⁰ However, they did not incorporate BVA or assess multiple modalities simultaneously within the same framework. By integrating all three therapies, our study addresses this critical gap and provides clinicians and researchers with comparative evidence to inform integrative treatment strategies.

Understanding how each acupuncture treatment performs could guide therapy selection. Since EA, LA, and BVA function through distinct mechanisms, such as electrical stimulation, PBM, and biochemical immune modulation, understanding their relative effects in one system may inform future combined or personalized protocols. We prioritized functional and structural outcomes over molecular testing to ensure that our findings were closely related to the clinical characteristics of OA.

Conclusion

Acupuncture reduced both pain behaviors and cartilage degeneration in MIA-induced KOA, but the benefit was contingent upon the specific modality employed. LA had the most substantial and persistent therapeutic results, as indicated by changes in pain thresholds, cartilage, and bone structure. Its effectiveness outperformed that of EA and MA. In contrast, BVA had little efficacy and caused acute adverse reactions. This study suggests that the therapeutic efficacy of acupuncture for KOA is determined by the modality used, with laser-based approaches outperforming other methods. These findings emphasize the potential for adapting acupuncture modalities to disease pathophysiology and the importance of integrative, comparative research in advancing complementary OA therapies.

Abbreviations

BVA, bee venom acupuncture; CT, computed tomography; EA, electroacupuncture; EDTA, ethylenediaminetetraacetic acid; GB34, gall bladder 34 acupoint (yanglingquan); LA, laser acupuncture, MA, manual acupuncture; MIA, monosodium iodoacetate; OA, osteoarthritis; PWT, paw withdrawal threshold; PBM, photobiomodulation.

Data Sharing Statement

The data generated for the present study are available from the corresponding author, Gihyun Lee: [email protected], and Jae-Hong Kim: [email protected], upon reasonable request.

Ethical Statement

This study was approved by the animal care and use committee of Dongshin University (DSU-2024-07-04).

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: RS-2023-KH139215).

Disclosure

The authors declare that they have no conflicts of interest in this work.

References

1. David J, Hunter P, Sita Bierma-Zeinstra P. Osteoarthritis. Lancet. 2019;1745–1759.

2. Safiri S, Kolahi -A-A, Smith E, et al. Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the global burden of disease study 2017. Ann Rheumatic Dis. 2020;79(6):819–828. doi:10.1136/annrheumdis-2019-216515

3. Conaghan PG, Dickson J, Grant RL. Care and management of osteoarthritis in adults: summary of NICE guidance. BMJ. 2008;336(7642):502–503. doi:10.1136/bmj.39490.608009.AD

4. O’Neil CK, Hanlon JT, Marcum ZA. Adverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesics. Am J Geriatric Pharmacother. 2012;10(6):331–342. doi:10.1016/j.amjopharm.2012.09.004

5. Janusz M, Hookfin E, Heitmeyer S, et al. Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis Cartilage. 2001;9(8):751–760. doi:10.1053/joca.2001.0472

6. Guingamp C, Gegout‐Pottie P, Philippe L, Terlain B, Netter P, Gillet P. Mono‐iodoacetate‐induced experimental osteoarthritis. A dose‐response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum. 1997;40(9):1670–1679. doi:10.1002/art.1780400917

7. Han J-S. Acupuncture and endorphins. Neurosci Lett. 2004;361(1–3):258–261. doi:10.1016/j.neulet.2003.12.019

8. Kamau V, Lee G, Kim JH. Therapeutic effects of invasive laser acupuncture at GB34 on monosodium iodoacetate-induced osteoarthritis rats. Osteoarthritis Cartilage. 2025;33:S477. doi:10.1016/j.joca.2025.02.697

9. Chen S, Zhang GY, Wang YY, et al. Effect of moxibustion and scraping on bioactive substances of acupoints in knee osteoarthritis rats. Zhen Ci Yan Jiu. 2023;48(4):359–365. doi:10.13702/j.1000-0607.20220994

10. Lee J-H, Choi T-Y, Lee MS, Lee H, Shin B-C, Lee H. Acupuncture for acute low back pain: a systematic review. Clin J Pain. 2013;29(2):172–185. doi:10.1097/AJP.0b013e31824909f9

11. Lee H-S, Park J-B, Seo J-C, Park H-J, Lee H-J. Standards for reporting interventions in controlled trials of acupuncture: the STRICTA recommendations. J Acupuncture Res. 2002;19(6):134–154.

12. MacPherson H, White A, Cummings M, et al. Standards for reporting interventions in controlled trials of acupuncture: the STRICTA recommendations. Acupuncture Med. 2002;20(1):22–25. doi:10.1136/aim.20.1.22

13. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American college of rheumatology/arthritis foundation guideline for the management of osteoarthritis of the hand, Hip, and knee. Arthritis Rheumatol. 2020;72(2):220–233. doi:10.1002/art.41142

14. Manheimer E, Linde K, Lao L, Bouter LM, Berman BM. Meta-analysis: acupuncture for osteoarthritis of the knee. Ann Internal Med. 2007;146(12):868–877. doi:10.7326/0003-4819-146-12-200706190-00008

15. Manheimer E, Cheng K, Linde K, et al. Acupuncture for peripheral joint osteoarthritis. Cochrane Database Syst Rev. 2010;2010(1). doi:10.1002/14651858.CD001977.pub2

16. Corbett M, Rice S, Madurasinghe V, et al. Acupuncture and other physical treatments for the relief of pain due to osteoarthritis of the knee: network meta-analysis. Osteoarthritis Cartilage. 2013;21(9):1290–1298. doi:10.1016/j.joca.2013.05.007

17. Chen J, Liu A, Zhou Q, et al. Acupuncture for the treatment of knee osteoarthritis: an overview of systematic reviews. Int J Gene Med. 2021;Volume 14:8481–8494. doi:10.2147/IJGM.S342435

18. Lee J-D, Park H-J, Chae Y, Lim S. An overview of bee venom acupuncture in the treatment of arthritis. Evidence-Based Complementary Alternative Med. 2005;2(1):79–84. doi:10.1093/ecam/neh070

19. Cherniack EP, Govorushko S. To bee or not to bee: the potential efficacy and safety of bee venom acupuncture in humans. Toxicon. 2018;154:74–78. doi:10.1016/j.toxicon.2018.09.013

20. Kim M, Lee Y, Choi D, Youn D, Na C. Effects of laser and electro acupuncture treatment with GB30· GB34 on change in arthritis rat. Korean J Acupuncture. 2019;36(4):189–199. doi:10.14406/acu.2019.023

21. Law D, McDonough S, Bleakley C, Baxter GD, Tumilty S. Laser acupuncture for treating musculoskeletal pain: a systematic review with meta-analysis. J Acupuncture Meridian Studies. 2015;8(1):2–16. doi:10.1016/j.jams.2014.06.015

22. Chen W, Zhang X-N, Su Y-S, et al. Electroacupuncture activated local sympathetic noradrenergic signaling to relieve synovitis and referred pain behaviors in knee osteoarthritis rats. Front Mol Neurosci. 2023;16:1069965. doi:10.3389/fnmol.2023.1069965

23. Zhang W, Zhang L, Yang S, Wen B, Chen J, Chang J. Electroacupuncture ameliorates knee osteoarthritis in rats via inhibiting NLRP3 inflammasome and reducing pyroptosis. Mol Pain. 2023;19:17448069221147792. doi:10.1177/17448069221147792

24. Ro JY, Zhang Y, Tricou C, Yang D, da Silva JT, Zhang R. Age and sex differences in acute and osteoarthritis-like pain responses in rats. J Gerontol Ser A. 2020;75(8):1465–1472.

25. Tan Q, Cai Z, Li J, et al. Imaging study on acupuncture inhibiting inflammation and bone destruction in knee osteoarthritis induced by monosodium iodoacetate in rat model. J Pain Res. 2022;Volume 15:93–103. doi:10.2147/JPR.S346242

26. Bove S, Calcaterra S, Brooker R, et al. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage. 2003;11(11):821–830. doi:10.1016/S1063-4584(03)00163-8

27. Ma Y, Guo H, Bai F, et al. A rat model of knee osteoarthritis suitable for electroacupuncture study. Experimental animals. 2018;67(2):271–280. doi:10.1538/expanim.17-0142

28. Kim J-H, Na C-S, Cho M-R, Park G-C, Lee J-S. Efficacy of invasive laser acupuncture in treating chronic non-specific low back pain: a randomized controlled trial. PLoS One. 2022;17(5):e0269282. doi:10.1371/journal.pone.0269282

29. Li Y, Wu F, Wei J, Lao L, Shen X. The effects of laser moxibustion on knee osteoarthritis pain in rats. Photobiomodul Photomed Laser Surg. 2020;38(1):43–50. doi:10.1089/photob.2019.4716

30. Chon TY, Mallory MJ, Yang J, Bublitz SE, Do A, Dorsher PT. Laser acupuncture: a concise review. Med Acupuncture. 2019;31(3):164–168. doi:10.1089/acu.2019.1343

31. Chen J, Lariviere WR. The nociceptive and anti-nociceptive effects of bee venom injection and therapy: a double-edged sword. Progress Neurobiol. 2010;92(2):151–183. doi:10.1016/j.pneurobio.2010.06.006

32. Kwon Y-B, Lee J-D, Lee H-J, et al. Bee venom injection into an acupuncture point reduces arthritis associated edema and nociceptive responses. Pain. 2001;90(3):271–280. doi:10.1016/S0304-3959(00)00412-7

33. Lee JA, Son MJ, Choi J, Jun JH, Kim J-I, Lee MS. Bee venom acupuncture for rheumatoid arthritis: a systematic review of randomised clinical trials. BMJ open. 2014;4(11):e006140. doi:10.1136/bmjopen-2014-006140

Introduction

Inflammatory Bowel Disease (IBD) is a chronic, relapsing condition that primarily includes Crohn’s disease (CD) and ulcerative colitis (UC).¹ IBD most commonly affects young adults, with peak incidence between the ages of 15 and 30 years, and a smaller peak occurring in later adulthood.^2,3 These diseases are characterized by inflammation of the gastrointestinal tract, leading to significant morbidity and disability.⁴ Symptoms such as abdominal pain, diarrhea, and weight loss can severely impact quality of life and result in substantial healthcare costs. Globally, the economic burden of IBD is substantial, with significant implications for healthcare systems worldwide.^5–9 In the United States alone, IBD affects over 3 million individuals and is a leading cause of death and disability among digestive diseases.¹⁰ Despite a decrease in prevalence from 1990 to 2019, the mortality rate for IBD in the US increased by 172%, and Disability Adjusted Life Years (DALYs) rose by 16%, indicating a growing burden on the healthcare system.¹⁰ The economic impact of IBD is multifaceted, involving direct costs such as hospitalizations, medications, and outpatient care, as well as indirect costs related to lost productivity and long-term disability.

Compared with traditional therapies such as corticosteroids, aminosalicylates, and immunomodulators, which mainly provide nonspecific immunosuppression or symptomatic relief, biologic therapies offer targeted modulation of key inflammatory pathways.⁴ With the advent of biologic therapies, there has been a substantial improvement in the management of IBD.^11,12 Biologics, such as anti-tumor necrosis factor (TNF) agents, have revolutionized the treatment landscape by providing effective control of inflammation and reducing the need for surgery. These therapies have enabled many patients to achieve and maintain remission, significantly improving their quality of life and long-term outcomes.

However, treating IBD in women of reproductive age presents unique challenges. The safety of biologic therapies during pregnancy and breastfeeding is a critical concern that requires careful consideration and management.^13–15 Evidence indicates that maintaining remission is crucial, as uncontrolled IBD itself increases risks of preterm birth and low birth weight. Anti-TNF agents and newer IL-23 inhibitors are generally considered safe, while discontinuation during pregnancy raises relapse risk.¹³ Surgical history also matters, since procedures such as ileal pouch–anal anastomosis (IPAA) can reduce fertility.¹⁵ In addition, women with IBD have higher rates of cesarean section and adverse maternal outcomes compared with women without IBD.¹⁵

Moreover, IBD can profoundly impact the psychological well-being of women in this age group, who often face additional stress due to their roles in family and work.¹⁶ The burden of IBD may significantly affect their social roles and overall quality of life.^17,18 Therefore, understanding the epidemiology of IBD specifically in women of reproductive age is essential for developing targeted interventions and support mechanisms. In particular, by disaggregating the reproductive-age population into seven 5-year age bands and applying the Nordpred model for age-specific projections, this study offers novel insights beyond prior GBD-based analyses.

Methods

Data Source

This study utilizes data from the 2021 Global Burden of Disease (GBD) study, which provides comprehensive estimates on the incidence, prevalence, years lived with disability (YLDs), DALYs, and healthy life expectancy (HALE) for 371 diseases and injuries across 204 countries and territories, encompassing 811 subnational regions.^19,20 Specifically, our research examines the burden of IBD among women of reproductive age from 1992 to 2021. The age groups included in this study are: 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, and 45–49 years. Data collected includes the number of cases, incidence rates, mortality rates, and DALY rates. This research adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for reporting observational epidemiological studies.

Socio-Demographic Index (SDI)

Developed by GBD researchers, the SDI is a composite indicator of development status that is strongly correlated with health outcomes. The SDI is the geometric mean of three key indices, each ranging from 0 to 1: the total fertility rate under the age of 25 (TFU25), the mean education level for individuals aged 15 and older (EDU15+), and the lag-distributed income (LDI) per capita. A location with an SDI of 0 represents a theoretical minimum level of development relevant to health, while an SDI of 1 represents a theoretical maximum level. In this study, we used SDI to stratify countries and regions into five categories (low, low-middle, middle, high-middle, and high) to analyze the burden of IBD among women of reproductive age. This stratification helps to understand how socio-demographic factors influence the incidence, prevalence, mortality, and DALYs associated with IBD in different development settings.

Statistical Analysis

We conducted a comprehensive statistical analysis to assess the burden of IBD among women of reproductive age from 1992 to 2021. Incidence rates, mortality rates, and DALYs rates were calculated per 100,000 population for each year and age group (15–19, 20–24, 25–29, 30–34, 35–39, 40–44, and 45–49 years). The 95% uncertainty intervals (UIs) for these estimates were derived from 1000 bootstrap replications to account for variability and ensure robustness.¹⁹

To evaluate trends over time, we computed the estimated annual percentage change (EAPC) for incidence rates, mortality rates, and DALYs rates using joinpoint regression analysis. We investigated the relationship between socio-demographic factors and the burden of IBD by stratifying data according to the SDI. To explore non-linear associations between SDI and IBD outcomes, we used loess smoothing. Additionally, Spearman’s rank correlation was applied to examine linear trends and the impact of different SDI levels on the burden of IBD.²¹ In our predictive analysis, we employed the Nordpred model, which utilizes age-period-cohort analysis to forecast future disease trends. This method provides a structured framework for estimating future health scenarios based on historical data and demographic dynamics.²² Our analysis was conducted on a global scale, with a specific focus on forecasting IBD trends across different age groups of women of reproductive age. This approach allows us to capture both the overall global burden and the specific impacts within this critical demographic. All analyses were done in R 4.3.3 with packages: ggplot2, sf, segmented, broom, dplyr, tidyr, INLA, BAPC.

Results

Inflammatory Bowel Disease in Women of Reproductive: Global Trends

Incidence

In 2021, the global incidence of IBD among women of reproductive age was 98,974.56 cases (95% UI: 80,567.63–124,088.76). This represents a 55.04% increase from the 63,839.03 cases (95% UI: 52,841.67–78,582.08) reported in 1992. The incidence rate increased from 4.61 per 100,000 population (95% UI: 3.82–5.68) in 1992 to 5.08 per 100,000 population (95% UI: 4.13–6.37) in 2021, with an EAPC of 0.43 (95% CI: 0.28–0.58) (Table 1). In 2021, the highest incidence rate was observed in the age group of 45–49 years, with a rate of 8.11 per 100,000 population, whereas the lowest incidence rate was found in the 15–19 years age group, with a rate of 1.40 per 100,000 population (Figure 1). Between 1992 and 2021, the age group 40–44 years experienced the most significant change in incidence rates, with an increase of 0.53 per 100,000 population. Conversely, the 25–29 years age group had the smallest change, with an increase of only 0.05 per 100,000 population (Figure 2).

Table 1 Incidence of Inflammatory Bowel Disease Among Women of Reproductive Age at the Global and Regional Levels Between 1992 and 2021

Figure 1 Incidence, Death, and DALYs Numbers and Rates of Inflammatory Bowel Disease Among Women of Reproductive Age in 2021. (A) Number and rate of incidence; (B) Number and rate of death; (C) Number and rate of DALYs.

Figure 2 Trends in Inflammatory Bowel Disease Incidence, Death, and DALYs rates among women of reproductive age from 1992 to 2021. (A) Rate of incidence; (B) Rate of death; (C) Rate of DALYs.

Mortality

In 2021, the global number of deaths due to IBD among women of reproductive age was 2,586.76 (95% UI: 1,900.32–3,125.77). This represents a 40.83% increase from the 1,836.75 deaths (95% UI: 1,195.53–2,384.65) reported in 1992. The death rate remained relatively stable, with 0.13 deaths per 100,000 population (95% UI: 0.09–0.17) in 1992 and 0.13 deaths per 100,000 population (95% UI: 0.10–0.16) in 2021, with an EAPC of −0.07 (95% CI: −0.12 to −0.01) (Supplement Table 1). In 2021, the highest death rate was observed in the age group of 40–44 years, with a rate of 0.22 per 100,000 population, whereas the lowest death rate was found in the 15–19 years age group, with a rate of 0.03 per 100,000 population (Figure 1). Between 1992 and 2021, the age group 45–49 years experienced the most significant decrease in death rates, with a reduction of 0.08 per 100,000 population. Conversely, the 30–34 years age group had the smallest decrease, with a reduction of only 0.002 per 100,000 population (Figure 2).

DALYs

In 2021, the global number of DALYs due to IBD among women of reproductive age was 281,580.36 (95% UI: 223,989.19–349,965.81). This represents a 38.53% increase from the 203,259.52 DALYs (95% UI: 154,006.13–257,799.02) reported in 1992. The DALYs rate slightly decreased from 14.68 per 100,000 population (95% UI: 11.12–18.62) in 1992 to 14.45 per 100,000 population (95% UI: 11.49–17.96) in 2021 (Supplement Table 2). In 2021, the highest DALYs rate was observed in the age group of 40–44 years, with a rate of 23.38 per 100,000 population, whereas the lowest DALYs rate was found in the 15–19 years age group, with a rate of 3.19 per 100,000 population (Figure 1). Between 1992 and 2021, the age group 45–49 years experienced the most significant decrease in DALYs rates, with a reduction of 5.22 per 100,000 population. Conversely, the 25–29 years age group had the smallest change, with a decrease of only 0.001 per 100,000 population (Figure 2).

Inflammatory Bowel Disease in Women of Reproductive: Socio-Demographic Index Levels

Incidence

In 2021, the number of prevalent cases of IBD among women of reproductive age was highest in the High SDI region, with a total of 38,912.17 cases (95% UI: 32,056.09–47,182.84). The High SDI region also had the highest prevalence rate, at 16.00 per 100,000 population (95% UI: 13.18–19.40). The most significant increase in the number of cases from 1992 to 2021 was observed in the Middle SDI region, with an absolute increase of 9,764.68 cases. The Middle SDI region also exhibited the highest EAPC, with a value of 2.07 (95% CI: 1.81–2.33) (Table 1).

Mortality

From 1992 to 2021, the regions that experienced a decline in mortality rates for IBD among women of reproductive age, as indicated by the EAPC, included the High-middle SDI region with an EAPC of −1.64 (95% CI: −1.83 to −1.45), the Low-middle SDI region with an EAPC of −0.35 (95% CI: −0.42 to −0.28), and the Middle SDI region with an EAPC of −0.47 (95% CI: −0.60 to −0.34). In contrast, the High SDI region saw an increase in mortality rates, with an EAPC of 0.41 (95% CI: 0.06 to 0.75), as did the Low SDI region, with an EAPC of 0.13 (95% CI: 0.05 to 0.21). In 2021, the highest mortality rate was observed in the Low SDI region, at 0.27 per 100,000 population (95% UI: 0.16–0.36), whereas the lowest mortality rate was found in the High-middle SDI region, at 0.07 per 100,000 population (95% UI: 0.06–0.09) (Supplement Table 1).

DALYs

From 1992 to 2021, the EAPC analysis revealed that the Middle SDI region experienced the most significant increase in DALYs, with an EAPC of 0.39 (95% CI: 0.31–0.47). Conversely, the High-middle SDI region saw the most substantial decrease in EAPC, registering −0.39 (95% CI: −0.47 to −0.32). In 2021, the High SDI region exhibited the highest DALYs value for women of reproductive age (15–49 years) with IBD, reaching 75,867.33 (95% UI: 53,581.20–102,607.88). In contrast, the High-middle SDI region had the lowest DALYs value in 2021, recorded at 31,075.70 (95% UI: 23,755.44–40,083.38) (Supplement Table 2).

Inflammatory Bowel Disease in Women of Reproductive: Geographic Regional Trends

Incidence

In 2021, the highest number of incident cases of IBD among women of reproductive age was reported in High-income North America, with 19,864.53 cases (95% UI: 16,479.19–24,224.81). In contrast, Oceania had the fewest cases, with 30 cases (95% UI: 24–39). The region with the highest EAPC in incidence rates was East Asia, showing substantial growth over the period, with an EAPC of 3.40 (95% CI: 2.67–4.13). Oceania exhibited the lowest EAPC at 0.59 (95% CI: 0.55–0.62) (Table 1).

In 2021, the highest incidence rate was observed in High-income North America, with a rate of 23.64 per 100,000 population (95% UI: 19.61–28.83), while Oceania had the lowest incidence rate at 0.87 per 100,000 population (95% UI: 0.68–1.13). Among the 21 GBD regions, 8 regions had incidence rates above the global mean of 5.08 per 100,000 population (95% UI: 4.13–6.37), such as High-income North America, Southern Latin America, and Western Europe. In contrast, 13 regions, including Southeast Asia and East Asia, had incidence rates below the global mean (Table 1). Overall, a positive correlation is evident between SDI levels and IBD incidence rates, indicating that more developed regions experience higher rates of this disease (Figure 3).

Figure 3 Association SDI and Rates of Incidence, Death, and DALYs for Inflammatory Bowel Disease Among Women of Reproductive Age Across 21 GBD Regions from 1992 to 2021. (A) Incidence rate. (B) Death rate. (C) DALYs rate.

Mortality

In 2021, the highest number of deaths due to IBD among women of reproductive age was reported in South Asia, with 544.17 deaths (95% UI: 348.04–934.81). Oceania reported the fewest deaths, with 0.59 cases (95% UI: 0.31–0.94). The highest EAPC in mortality rates was in Australasia, with an EAPC of 2.69 (95% CI: 1.67–3.73), while High-income Asia Pacific had the lowest EAPC at −3.48 (95% CI: −3.78 to −3.17) (Supplement Table 1).

The highest mortality rate in 2021 was in Central Sub-Saharan Africa, at 0.09 per 100,000 population (95% UI: 0.05–0.14), and the lowest was in High-income North America, at 0.20 per 100,000 population (95% CI: 0.19–0.21). Among the 21 GBD regions, 7 regions had mortality rates above the global mean of 0.13 per 100,000 population (95% UI: 0.10–0.16), including Western Sub-Saharan Africa and Eastern Europe, while 14 regions, such as Southeast Asia and Australasia, had rates below the global mean (Supplement Table 1). Overall, the data reveal a strong inverse relationship between SDI levels and IBD mortality rates, highlighting that less developed regions are more heavily burdened by mortality due to IBD (Figure 3).

DALYs

In 2021, the highest number of DALYs due to IBD among women of reproductive age was reported in South Asia, with 67,327.10 DALYs (95% UI: 48,638.08–92,097.98). Oceania reported the fewest DALYs, with 68.95 DALYs (95% UI: 48.66–94.67) (Supplement Table 2).

The highest EAPC in DALY rates was in Central Latin America, with an EAPC of 1.15 (95% CI: 0.98–1.32), while Andean Latin America had the lowest EAPC at −1.57 (95% CI: −1.87 to −1.26). Among the 21 GBD regions, 9 regions had DALY rates above the global mean of 14.45 per 100,000 population, including Western Sub-Saharan Africa and Australasia, while 12 regions, such as Southeast Asia and East Asia, had rates below the global mean (Supplement Table 2). The graph depicts a U-shaped curve, indicating that both low and high SDI regions have higher DALY rates due to IBD, while middle SDI regions have lower rates (Figure 3).

Inflammatory Bowel Disease in Women of Reproductive: National Trends

Incidence

In 2021, the highest number of incident cases of IBD among women of reproductive age was reported in India, with 22,540.84 cases (95% UI: 18,131.75–28,645.95). The country with the highest EAPC in incidence rates was China, with an EAPC of 3.45 (95% CI: 2.71–4.19). On the other hand, Finland had the lowest EAPC at −1.85 (95% CI: −2.28 to −1.42) (Supplement Table 3).

The incidence rates of IBD among women of reproductive age in 2021 demonstrate a positive correlation with the SDI across 204 countries. High SDI countries, such as the Netherlands (32.38 per 100,000 population), Germany (26.99 per 100,000 population), and Norway (25.76 per 100,000 population), show relatively high incidence rates. In contrast, low SDI countries, such as the Lao People’s Democratic Republic (0.82 per 100,000 population) and Cambodia (0.83 per 100,000 population), exhibit significantly lower incidence rates. Middle SDI countries, including Kazakhstan (6.63 per 100,000 population) and the Kyrgyz Republic (5.28 per 100,000 population), present moderate incidence rates (Supplement Table 3). This pattern indicates that higher levels of socioeconomic development are associated with increased incidence rates of IBD (Figure 4).

Figure 4 Continued.

Figure 4 Relationship Between SDI and Rates of Incidence, Death, and DALYs for Inflammatory Bowel Disease Among Women of Reproductive Age in 204 Countries and Territories in 2021. (A) Incidence rates. (B) Death rates. (C) DALYs rates.

Mortality

In 2021, the highest number of deaths due to IBD among women of reproductive age was reported in India, with 357.21 deaths (95% UI: 203.56–652.99). The country with the highest EAPC in mortality rates was American Samoa, with an EAPC of 4.02 (95% CI: 2.84–5.22). Conversely, Singapore had the lowest EAPC at −8.05 (95% CI: −8.50 to −7.60) (Supplement Table 4).

The mortality rates due to IBD across countries in 2021 illustrate an inverse relationship with SDI levels. High SDI countries, such as Canada (0.13 per 100,000 population) and Australia (0.10 per 100,000 population), report relatively low mortality rates. In contrast, low SDI countries, such as Nigeria (0.56 per 100,000 population) and Ghana (0.71 per 100,000 population), experience significantly higher mortality rates. Middle SDI countries, including Kazakhstan (0.27 per 100,000 population) and Brazil (0.23 per 100,000 population), display moderate mortality rates (Supplement Table 4). This pattern highlights how socioeconomic development influences IBD mortality rates, with more developed regions achieving lower rates (Figure 4).

DALYs

In 2021, the highest number of DALYs due to IBD among women of reproductive age was reported in India, with 48,130.70 DALYs (95% UI: 34,218.65–67,011.34). The highest DALY rate was observed in Guinea-Bissau, with a rate of 87.33 per 100,000 population (95% UI: 47.06–141.34), while the lowest DALY rate was in the Solomon Islands, at 1.72 per 100,000 population (95% UI: 1.18–2.37). The country with the highest EAPC in DALY rates was Libya, with an EAPC of 2.67 (95% CI: 2.42–2.93). Conversely, Estonia had the lowest EAPC at −2.64 (95% CI: −3.66 to −1.60) (Supplement Table 5).

The DALY rates due to IBD across countries in 2021 demonstrate a U-shaped pattern when examined in relation to SDI levels (Figure 4). High SDI countries, such as Canada (76.20 per 100,000 population) and the United States (38.67 per 100,000 population), exhibit relatively elevated DALY rates. Similarly, low SDI countries, such as Nigeria (34.37 per 100,000 population) and Ghana (43.54 per 100,000 population), also report elevated DALY rates. In contrast, middle SDI countries, including Kazakhstan (24.27 per 100,000 population), Brazil (16.14 per 100,000 population), and Turkey (12.01 per 100,000 population), display moderate DALY rates (Supplement Table 5).

Inflammatory Bowel Disease in Women of Reproductive Age: Projected Global Trends (2021–2030)

From 2021 to 2030, the global burden of IBD among women of reproductive age is projected to decline gradually. In 2021, the number of IBD cases was estimated at 98,975, with an incidence rate of 5.08 per 100,000. By 2030, this number is expected to decrease to 94,773, with a corresponding incidence rate of 4.51 per 100,000. Despite this decrease, the number of deaths attributable to IBD is anticipated to rise slightly, from 2587 in 2021 to 2781 in 2030, while the mortality rate will remain stable at around 0.132 per 100,000. The DALYs associated with IBD are expected to increase slightly from 281,580 years in 2021 to 284,508 years in 2030, with the DALY rate changing from 14.45 per 100,000 in 2021 to 13.55 per 100,000 in 2030 (Supplement Table 6).

Age-specific trends reveal that the incidence of IBD increases progressively with age, peaking in the 45 to 49 age group by 2030, where the number of cases is projected to reach 21,213, with an incidence rate of 7.79 per 100,000. The incidence remains high in the 40 to 44 age group as well, with 20,736 cases and an incidence rate of 6.96 per 100,000. Correspondingly, the death rate is expected to escalate from 0.03 per 100,000 in the 15 to 19 age group to 0.21 per 100,000 in the 45 to 49 age group, with the 40 to 44 age group seeing a similar rate of 0.22 per 100,000. The DALYs rate will similarly rise with age, starting at 2.95 per 100,000 in the youngest group (15–19 years) and peaking at 21.42 per 100,000 in the 45 to 49 age group, closely followed by 21.18 per 100,000 in the 40 to 44 age group. These trends underscore the increasing burden of IBD with advancing age, particularly in the older reproductive age groups (Figure 5).

Figure 5 Global trends and projections of incidence, Death, and DALYs of inflammatory bowel disease among women of reproductive age (1992–2030). (A) Number and rate of incidence; (B) Number and rate of death; (C) Number and rate of DALYs.

Discussion

The burden of IBD has been increasing steadily, presenting a significant public health challenge,^5,7 particularly among women of reproductive age.²³ This demographic is unique due to the intersection of their reproductive health and the management complexities of IBD.²⁴ Our study conducted a comprehensive analysis of the global, regional, and national burden of IBD from 1992 to 2021, focusing on incidence, mortality, and DALYs. We further explored how these indicators varied across different regions and countries according to their SDI levels. This study provides crucial epidemiological evidence necessary for developing targeted public health strategies and interventions aimed at mitigating the impact of IBD on women of reproductive age, ultimately improving their quality of life and health outcomes.

Globally, the incidence, mortality, and DALYs associated with IBD among women of reproductive age have shown significant trends from 1992 to 2021. The incidence of IBD increased by 55.04%, from 63,839.03 cases in 1992 to 98,974.56 cases in 2021, with the incidence rate rising from 4.61 to 5.08 per 100,000 population. The highest incidence rate in 2021 was observed in women aged 45–49 years, whereas the lowest was in those aged 15–19 years. This suggests that older women within the reproductive age spectrum are more frequently diagnosed with IBD. As women age, the decline in immune regulation and significant alterations in gut microbiota may synergistically contribute to the increased risk and higher incidence of IBD.^25,26

Despite the increase in incidence, the overall mortality rate remained relatively stable, staying at around 0.13 deaths per 100,000 population. The highest mortality rate was observed in the 40–44 years age group, reaching 0.22 deaths per 100,000 population. However, DALYs increased by 38.53%, indicating a growing burden of disability. The age group of 45–49 years experienced the most significant increase in DALYs, highlighting the prolonged impact of IBD on older women within the reproductive age. This could be due to the chronic nature of the disease and its complications, including frequent relapses, long-term medication requirements, and surgeries, all of which impact quality of life.^27–29 Public health interventions must address these growing burdens to improve outcomes and quality of life for this vulnerable population.

The burden of IBD among women of reproductive age varies significantly across different socioeconomic contexts, as illustrated by the SDI. In regions with higher SDI, such as North America, Western Europe, and Australia, the incidence of IBD is markedly elevated. For instance, in economically developed regions like North America, IBD stands as a leading cause of disability and mortality among digestive diseases. This substantial disease burden necessitates robust healthcare interventions. Contributing to this higher incidence is the heightened awareness and availability of advanced diagnostic tools in these regions, including endoscopy, fecal calprotectin, and gastrointestinal ultrasound, which enhance IBD detection.^30,31 These diagnostic tools, combined with a high index of suspicion in primary care settings, facilitate earlier and more frequent diagnoses, potentially inflating incidence rates compared to regions with less developed healthcare infrastructures. Furthermore, these regions benefit from early detection, comprehensive management protocols, and greater access to advanced therapies, which together contribute to lower mortality rates, despite the higher prevalence of the disease.

Beyond diagnostic advances, therapeutic innovations—particularly the introduction of biologics since the late 1990s—have substantially improved the prognosis of IBD.³² Infliximab was first approved for Crohn’s disease in 1998 and subsequently for ulcerative colitis, with newer biologics such as IL-12/23 and IL-23 inhibitors further broadening treatment options.³³ Evidence from clinical trials and population-based studies indicates that biologics reduce hospitalization, surgery, and mortality, while improving quality-adjusted life years (QALYs).³⁴ These advances may help explain the stabilization or decline in mortality despite rising incidence, particularly in high-SDI regions where access to biologics is greater. Although GBD data cannot directly capture treatment effects, acknowledging these developments provides important context for interpreting observed trends and emphasizes the need for equitable access in reproductive-age women.

In contrast, lower SDI regions, such as Western Sub-Saharan Africa, exhibit lower incidence rates but face disproportionately higher mortality and DALY rates. This disparity is largely driven by inadequate healthcare infrastructure, limited access to advanced therapies, and delays in diagnosis, which exacerbate the disease burden.^34–36 Middle SDI regions, including Central Asia and Latin America, are currently navigating a transitional phase characterized by improvements in healthcare systems that have begun to enhance disease identification and management. Despite these advancements, these regions continue to face significant challenges in managing the chronic and debilitating nature of IBD, as reflected by the substantial increase in DALYs. This growing burden is compounded by the rapid urbanization and westernization in these areas, which contribute to a rising incidence of IBD.⁸ Addressing these disparities is essential for improving health outcomes and the quality of life for women of reproductive age affected by IBD, particularly as these regions confront the dual challenges of increasing prevalence and an aging population.

Finally, the projected trends in the global burden of IBD among women of reproductive age from 2021 to 2030 indicate important shifts across different age groups. While the overall incidence rate is projected to decrease slightly, the total number of cases remains substantial, particularly in the older segment of this age range. The mortality rate is expected to remain stable, yet an increase in the number of deaths is anticipated, reflecting population growth within this demographic. Additionally, a slight increase in DALYs is expected, especially among those aged 40–49, underscoring the ongoing challenge posed by the chronic nature of IBD. These projections highlight the necessity for targeted public health interventions, focusing on early diagnosis, effective disease management, and comprehensive support, to alleviate the long-term impact of IBD on this population.

Limitations

This study has several limitations. First, the reliance on GBD 2021 data, which incorporates modeled estimates, may introduce inaccuracies, particularly in low-income regions where data quality is less reliable. This could lead to an underestimation of the true burden of IBD in these areas. Additionally, the projections for IBD burden are based on historical trends and do not consider potential future interventions or policy changes that could alter these trends. Furthermore, the study was unable to analyze specific risk factors for IBD due to the limitations of the database used, which could have provided more insights for targeted interventions. Finally, ecological and environmental factors such as latitude, UV exposure, and vitamin D—known to be associated with IBD epidemiology—could not be assessed, as these indices are not included in the GBD 2021 dataset.

Conclusion

In conclusion, the global burden of IBD among women of reproductive age has significantly increased from 1992 to 2021, with the total number of cases rising by 55% and incidence rates showing a steady upward trend. This growth highlights the ongoing challenges posed by IBD on a global scale. Substantial variations are evident across different SDI regions. High SDI regions, while experiencing higher incidence rates and DALYs, have relatively lower mortality rates. In contrast, low SDI regions face a disproportionate burden, with higher mortality and DALYs despite lower incidence rates. Looking forward, projections to 2030 suggest a slight decrease in global incidence rates; however, the absolute number of cases and related deaths is expected to continue increasing, particularly among older women within the reproductive age range. These findings emphasize the urgent need for targeted public health interventions that focus on early diagnosis, effective management strategies, and comprehensive support systems, particularly in resource-limited settings.

Abbreviation

IBD, Inflammatory Bowel Disease; GBD, Global Burden of Disease; DALYs, Disability-Adjusted Life Years; EAPC, Estimated Annual Percentage Change; SDI, Socio-Demographic Index; CD, Crohn’s disease; UC, Ulcerative Colitis; TNF, Tumor Necrosis Factor; YLDs, Years Lived with Disability; HALE, Healthy Life Expectancy.

Data Sharing Statement

The data can be obtained from a public, open-access database. Information regarding data access policies and procedures can be found at https://ghdx.healthdata.org/gbd-2021.

Ethics Approval and Consent to Participate

This study used only de-identified, publicly available data from the Global Burden of Disease (GBD) 2021 database. The Ethics Committee of Xiangyang No.1 People’s Hospital determined that formal approval was not required.

Acknowledgments

We would like to express our heartfelt appreciation to the Global Burden of Disease Collaborative Network and the Institute for Health Metrics and Evaluation (IHME) for their invaluable support. We sincerely thank the editor and reviewers for their valuable feedback, which has greatly improved the quality of our manuscript.

Author Contributions

All authors made a significant contribution to the work reported, whether in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

No external funding was received for the study.

Disclosure

The authors declare that they have no competing interests in this work.

References

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–429. doi:10.1056/NEJMra020831

2. Johnston RD, Logan RF. What is the peak age for onset of IBD? Inflamm Bowel Dis. 2008;14(Suppl 2):S4–5. doi:10.1002/ibd.20545

3. Zimmerman J, Gavish D, Rachmilewitz D. Early and late onset ulcerative colitis: distinct clinical features. J Clin Gastroenterol. 1985;7:492–498. doi:10.1097/00004836-198512000-00010

4. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–1657. doi:10.1016/S0140-6736(07)60751-X

5. Park J, Jeong GH, Song M, et al. The global, regional, and national burden of inflammatory bowel diseases, 1990–2019: a systematic analysis for the global burden of disease study 2019. Dig Liver Dis. 2023;55:1352–1359. doi:10.1016/j.dld.2023.04.003

6. Zhang ZM, Lin ZL, He BX, et al. Epidemiological analysis reveals a surge in inflammatory bowel disease among children and adolescents: a global, regional, and national perspective from 1990 to 2019 – insights from the China study. J Glob Health. 2023;13:04174. doi:10.7189/jogh.13.04174

7. Alatab S, Sepanlou SG, Ikuta K. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30. doi:10.1016/S2468-1253(19)30333-4

8. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18:56–66. doi:10.1038/s41575-020-00360-x

9. Zhang Z, Du N, Xu C, Chen W, Chen T, Xiao Y. Global, regional, and national burden of inflammatory bowel disease in persons aged 60–89 years from 1992 to 2021. BMC Gastroenterol. 2025;25:425. doi:10.1186/s12876-025-04042-3

10. Rahul Patel VRSK, Roy V, Kunhipurayil S. Trends of inflammatory bowel disease burden in the United States (1990–2019), projections of deaths to 2040: insights from the 2019 global burden of disease study. Gastroenterology. 2024;166:S57. doi:10.1053/j.gastro.2023.11.137

11. Tursi A, Mocci G, Lorenzetti R, et al. Long-term real-life efficacy and safety of infliximab and Adalimumab in the treatment of inflammatory bowel diseases outpatients. Eur J Gastroenterol Hepatol. 2021;33:670–679. doi:10.1097/MEG.0000000000002087

12. Kamal ME, Werida RH, Radwan MA, et al. Efficacy and safety of infliximab and Adalimumab in inflammatory bowel disease patients. Inflammopharmacology. 2024;32(5):3259–3269. doi:10.1007/s10787-024-01508-w

13. Nielsen OH, Gubatan JM, Kolho KL, Streett SE, Maxwell C. Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation. Lancet. 2024;403:1291–1303. doi:10.1016/S0140-6736(24)00052-7

14. de Lima A, Zelinkova Z, van der Ent C, Steegers EA, van der Woude CJ. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut. 2016;65:1261–1268. doi:10.1136/gutjnl-2015-309321

15. Shand AW, Chen JS, Selby W, Solomon M, Roberts CL. Inflammatory bowel disease in pregnancy: a population-based study of prevalence and pregnancy outcomes. BJOG. 2016;123:1862–1870. doi:10.1111/1471-0528.13946

16. Truta B. The impact of inflammatory bowel disease on women’s lives. Curr Opin Gastroenterol. 2021;37:306–312. doi:10.1097/MOG.0000000000000736

17. Pittet V, Vaucher C, Froehlich F, Burnand B, Michetti P, Maillard MH. Patient self-reported concerns in inflammatory bowel diseases: a gender-specific subjective quality-of-life indicator. PLoS One. 2017;12:e0171864. doi:10.1371/journal.pone.0171864

18. Ronchetti C, Cirillo F, Di Segni N, Cristodoro M, Busnelli A, Levi-Setti PE. Inflammatory bowel disease and reproductive health: from fertility to pregnancy-A narrative review. Nutrients. 2022;15:14. doi:10.3390/nu15010014

19. Ferrari AJ, Santomauro DF, Aali A, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403:2133–2161. doi:10.1016/S0140-6736(24)00757-8

20. Brauer M, Roth GA, Aravkin AY, et al. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403:2162–2203. doi:10.1016/S0140-6736(24)00933-4

21. Zhang K, Kan C, Han F, et al. Global, regional, and national epidemiology of diabetes in children from 1990 to 2019. JAMA Pediatrics. 2023;177:837. doi:10.1001/jamapediatrics.2023.2029

22. Luo G, Zhang Y, Etxeberria J, et al. Projections of lung cancer incidence by 2035 in 40 countries worldwide: population-based study. JMIR Public Health Surveill. 2023;9:e43651. doi:10.2196/43651

23. Wang R, Li Z, Liu S, Zhang D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the global burden of disease study 2019. BMJ Open. 2023;13:e065186. doi:10.1136/bmjopen-2022-065186

24. Laube R, Selinger CP, Seow CH, et al. Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding. Gut. 2023;72:1040–1053. doi:10.1136/gutjnl-2022-329304

25. Caetano-Silva ME, Shrestha A, Duff AF, et al. Aging amplifies a gut microbiota immunogenic signature linked to heightened inflammation. Aging Cell. 2024;23:e14190. doi:10.1111/acel.14190

26. Magrone T, Jirillo E. The interaction between gut microbiota and age-related changes in immune function and inflammation. Immun Ageing. 2013;10:31. doi:10.1186/1742-4933-10-31

27. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol. 1995;30:699–706. doi:10.3109/00365529509096316

28. Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology. 1992;103:1444–1451. doi:10.1016/0016-5085(92)91163-X

29. Kennedy NA, Warner B, Johnston EL, et al. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Aliment Pharmacol Ther. 2016;43:910–923. doi:10.1111/apt.13547

30. Jayasooriya N, Baillie S, Blackwell J, et al. Systematic review with meta-analysis: time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease. Aliment Pharmacol Ther. 2023;57:635–652. doi:10.1111/apt.17370

31. Ali S, Tamboli CP. Advances in epidemiology and diagnosis of inflammatory bowel diseases. Curr Gastroenterol Rep. 2008;10:576–584. doi:10.1007/s11894-008-0105-9

32. Ma C, Jairath V, Feagan BG, et al. Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2024;21:792–808. doi:10.1038/s41575-024-00989-y

33. Annese V, Duricova D, Gower-Rousseau C, Jess T, Langholz E. Impact of new treatments on hospitalisation, surgery, infection, and mortality in IBD: a focus paper by the Epidemiology Committee of ECCO. J Crohns Colitis. 2016;10:216–225. doi:10.1093/ecco-jcc/jjv190

34. Fischer WN, Wohl DA. Inequities in access to diagnostics threatens global public health security. Lancet Infect Dis. 2022;22:754–756. doi:10.1016/S1473-3099(21)00806-9

35. Adebusoye FT, Tenkorang PO, Awuah WA, et al. Terrorism’s impact on low and middle-income countries’ healthcare services: a perspective. J Public Health Res. 2024;13:22799036241231544. doi:10.1177/22799036241231544

36. Asombang A, Bhat P. Endoscopy and Its Alternatives in Resource-Limited Countries in Africa. Tech Innov Gastrointest Endosc. 2024;26:283–297. doi:10.1016/j.tige.2024.06.004

The Dutch government said on Sunday that it had taken the “highly exceptional” decision to intervene at Chinese-owned chipmaker Nexperia over a potential “risk to Dutch and European economic security.”

The Netherlands-based firm’s owner Wingtech said on Monday that it will take actions to protect its rights and will seek government support.

The development threatens to raise tensions between the European Union and China, which have increased in recent months over trade and Beijing’s relationship with Russia.

Nexperia was forced to sell its silicon chip plant in Newport, Wales after MPs and ministers expressed national security concerns. It currently owns a UK facility in Stockport.

The Dutch government said its economic affairs ministry had invoked its Goods Availability Act over “acute signals of serious governance shortcomings” within Nexperia.

The law is designed to allow the Hague to intervene in companies under exceptional circumstances. These include threats to the country’s economic security and to ensure the supply of critical goods.

The intervention is meant to prevent a potential situation in which Nexperia’s chips would become unavailable in an emergency, said the Dutch government.

It added that Nexperia’s operations posed a “threat to the continuity and safeguarding on Dutch and European soil of crucial technological knowledge and capabilities.”

The company’s production can continue as normal, it added.

Nexperia makes semiconductors used in cars and consumer electronics.

The government statement did not detail why it thought the firm’s operations were risky. The BBC has contacted Dutch authorities for clarification.

Shanghai-listed shares in Nexperia’s parent company Wingtech fell by 10% on Monday morning.

Wingtech is among the firms the US has placed on its so-called “entity list”. Under the regulations, US companies are barred from exporting American-made goods to businesses on the list unless they have special approval.

In September, the US commerce department further tightened its restrictions, adding to the entity list any company that is majority-owned by a Chinese firm.